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Cytolethal distending toxin (CDT) of C. jejuni, a leading cause of intestinal illness 
worldwide, and H. hepaticus, a laboratory mice pathogen causes cell cycle arrest and 
induces apoptosis in eukaryotic cells. In the present studies, the interactions of CDT 
with host innate defense mechanisms were investigated within the context of intestinal 
infection. The acute stage of intestinal infection by C. jejuni is characterized by 
massive transepithelial migration of activated PMNs into the intestinal lumen. 
Recently, neutrophil extracellular traps (NETs) have emerged as an important innate 
host defense mechanism against bacterial pathogens. We hypothesize that CDT 
nuclease mediates resistance against extracellular killing in NETs. First, NETs were 
discovered to capture C. jejuni in non-human primates with acute campylobacteriosis. 
The lack of direct induction of NETs formation in vitro by C. jejuni indicates NETs 
formation in C. jejuni infection might be indirectly mediated by components present 
within the intestinal microenvironment. Although C. jejuni were efficiently captured 
within NETs, they themselves did not induce NET fromation. However, once captured, 
C. jejuni survived within NETs, and CDT did not play a role in escape of C. jejuni 
from NETs. Taken together, the data suggest that within the context of the intestinal 
tract, NETs likely provide innate defense by a mechanism of bacterial exclusion and 
disposal by intestinal peristalsis.  
 
  
Given that CDT-induced intoxication of epithelial cells leads to a DDR, we 
hypothesized that CDT-intoxicated intestinal epithelial cells display a senescence-
associated secretory phenotype (SASP). Following treatment of human intestinal 
epithelial cells with sub-lethal doses of CDT from either C. jejuni or H. hepaticus or C. 
jejuni whole cell lysates, we observed persistent DDR including cell growth arrest and 
upregulation of γ-H2AX, accumulation of intracytoplasmic beta-galactosidase, and 
expression of pro-inflammatory cytokines IL-6 and IL-24 and CXCL-8 chemokine 
characteristic of SASP. In sum, the data reveal that activation of senescence pathways 
is a novel and potentially important downstream mechanism of CDT-induced 
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Cytolethal Distending Toxin 
 
Cytolethal distending toxin (CDT) was first discovered about 27 years ago from the 
culture filtrates of Escherichia coli (1) and Campylobacter jejuni (2), and it was 
defined as a heat labile toxin factor that caused progressive mammalian cell 
distension. After the genes encoding E. coli CDT (EcolCDT) were cloned and 
sequenced (3), the molecular biology and pathogenetic mechanisms of disease were 
widely investigated. To date, CDT has been found in over two dozen of Gram-
negative human and animal mucocutaneous bacterial pathogens primarily associated 
with major food- and water-borne diseases including Helicobacter hepaticus and 
several serotypes of Salmonella enterica (4). 
 
With the exception of the intestinal pathogen S. enterica which encodes only the CdtB 
subunit (5-7), CDT from all other bacterial pathogens consists of cdtA, cdtB, and cdtC 
genes, respectively encoding the corresponding tripartite polypeptide subunits A, B, 
and C. The CDT holotoxin displays features of an AB type 2 component toxin, in 
which the “A” component, represented by CdtB, is the biologically active subunit, 
while the “B” component, represented by CdtA and CdtC, binds to host cell lipid raft 
membrane microdomains and assists in the delivery of CdtB into host cell cytoplasm 
(8-10). The mechanism of CDT uptake into target cells and its intracellular trafficking 
are incompletely understood. A receptor-mediated uptake process has been proposed 
for CDT; however, the exact receptor is controversial. Actinobacillus 
actinomycetemcomitans CDT (AactCDT) co-localizes with GM1-enriched membrane 
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fractions and their association is reduced by cholesterol depletion (10). Inactivation of 
SGMS1 and TMEM181 genes in mammalian cells results in reduced cell cycle arrest 
induction by EcolCDT; TMEM181 binds EcolCDT and might be part of the complex 
on the cell surface that interacts with CDT (11).  After up take into host cells, 
Haemophilus ducreyi CDT (HducCDT) is transported from the endoplasmic reticulum 
(ER) to the Golgi complex through a retrograde pathway; blocking of CDT 
internalization abolishes its cytotoxicity (12).  No evidence shows the translocation of 
CDT from ER to cytosol, and the active CdtB subunit may move directly from ER into 
nucleus (12, 13). Disruption of endosome acidification prevents HducCDT-mediated 
cell cycle arrest, but not EcolCDT-induced cell cycle arrest, suggesting at least two 
different endocytic pathways before reaching the nucleus. These divergent pathways 
correlate with low CdtA and CdtC sequences identity (22% and 19%) between these 
two bacterial species (14). 
 
The B subunit displays conserved structural and functional homologies to members of 
the phosphodiesterase family including mammalian deoxyribonuclease I (DNase I) 
(8). Recombinant CdtB is capable of digesting plasmid DNA in vitro (8, 15). 
Endonuclease inhibitors prevent intoxication of B cells by recombinant CDT, 
suggesting cellular toxicity of CdtB is mediated by its nuclease activity (16). 
Furthermore, CdtB alone exhibits intracellular DNase I activity characterized by 
disruption and induction of G2/M cell cycle arrest, when expressed transiently, or 
microinjected into mammalian cells (17). Demonstration of DNA double-strand 
breaks (DSB) together with γ-H2AX expression following intoxication of HeLa cells 
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with HducCDT confirmes CDT-induced DNA damage results in a DNA damage 
response (DDR) (18, 19). Consistent with these observations is activation of tumor 
suppressor p53, cyclin dependent kinase inhibitor p21 and check point kinase CHK2 
in HducCDT treated fibroblasts and keratinocytes and delayed DDR in HducCDT-
intoxicated Ataxia Telangiectasia-mutated gene (ATM)-deficient lymphoblastoid cell 
lines (20). Fibroblasts exposed to HhepCDT exhibit MYC and ATM-dependent 
checkpoint activation similar to ionizing radiation-induced DDR (21). HducCDT 
induces DSB in HeLa cells similar to ionizing radiation, and activation of ATM-
dependent RhoA GTPase leads to actin cytoskeleton rearrangement (18). Rad50 foci, 
which are involved in telomere maintenance and DNA damage (22), are also formed 
around the DSB in primary human fibroblasts intoxicated with CjejCDT (23).  
 
It is generally accepted, in response to CDT induced DSB, activated ATM initiates 
DDR including activation of γ-H2AX, CHK2, p53 and p21, which in turn results in 
cell cycle arrest. The cell cycle arrest allows repair of the damaged DNA. CDT from 
many bacterial species also induces apoptosis in various cell lines including fibroblast, 
endothelial cell, epithelial and lymphoid (4). Few studies from a single investigator 
using human lymphoid cell lines have reported that CDT also displays 
phosphatidylinositol (PI)-3,4,5-triphosphate (PIP3) phosphatase activity (24, 25), and 
might contribute to host immune response modulation. Cytotoxicity of CDT observed 
in studies differs according to target cells, toxin preparation including bacterial source, 
method of purification and resulting specific activity and concentration. CDT arrests 
epithelial and endothelial cell lines at G2/M phase (9, 26-28), and fibroblast cell lines 
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at either G1/S or G2/M phase (20, 23, 29). Immune cells appear to be more sensitive to 
CDT, and usually undergo apoptosis after a short cell cycle arrest (20, 29, 30).  
 
In our study, C. jejuni and H. hepaticus were used to investigate the role of CDT in 
host innate immune defense and pathogenesis of CDT within the context of the 
intestinal tract by using the human intestinal epithelial INT407 cell line.  
 
Helicobacter hepaticus  
 
The prototype for enterohepatic Helicobacter species, H. hepaticus is a spiral Gram 
negative microaerophilic bacteria, which was originally isolated from A/JCr, and later 
from several strains of inbred laboratory mice with chronic active hepatitis (31, 32). H. 
hepaticus colonizes the lower intestine and hepatobiliary tracts of susceptible inbred 
strains of mice causing persistent typhlocolitis and hepatitis leading to hepatocellular 
carcinoma (6, 31-37). H. hepaticus DNA has also been detected by PCR of specimens 
obtained from patients with biliary disease (38), hepatocellular carcinoma (39), 
cholangiocarcinoma, and inflammatory bowel disease (39, 40). Experimental infection 
of mice with H. hepaticus has been used to investigate inflammatory bowel disease 
(41) and bacteria-induced neoplastic diseases of the intestine, liver and mammary 
gland (40, 42, 43).  
 
The complete genome of H. hepaticus reveals that genome content varies in different 
strains with many orthologs of C. jejuni. Most importantly, CDT is the only known 
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virulence factor found in H. hepaticus (44), its role in the pathogenesis of H. hepaticus 
infection and disease are incompletely understood (45-47). We reported previously 
that H. hepaticus CDT causes apoptotic cell death of intestinal epithelial cells through 
the mitochondrial pathway (48). HhepCDT also cause cell cycle arrest in human 
epithelial cell line in vitro (49). These observations are consistent with induction of 
apoptotic cell death in hepatitis and hepatocellular carcinoma of laboratory mice 
infected with H. hepaticus (6, 36, 39, 50, 51). CDT-deficient H. hepaticus fail to 
colonize the large intestine persistently in IL-10 knockout mice and cause less severe 




Campylobacter jejuni is a Gram-negative bacterial pathogen which is the leading 
cause of food-borne diarrhea in humans worldwide. Prevalence of C. jejuni infection 
in the US is second closely behind Salmonella, and is about 14 laboratory-confirmed 
cases per 100,000 population in 2011 excluding many more undiagnosed and 
unreported cases (52); thus from the current total population of 316.5 million, 4.4 
million people develop campylobacteriosis each year. According to a CDC estimate 
(52); Campylobacter infection affects approximately 0.8% or 25.3 million of the US 
population each year. Most of the Campylobacter infection is caused by C. jejuni, 
which are microaerobic, motile, spiral to curve-shaped, flagellated Gram negative 
bacteria that colonize the intestinal tract (53). The main sources of human infections 
are consumption and handling of contaminated poultry and the ingestion of 
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contaminated water (54, 55). Clinical signs range from mild, watery diarrhea to severe 
inflammatory bloody diarrhea, which last between 24-48 h, but generally, resolve 
within 10 days (54, 56). Although the infection is self-limiting in healthy persons, 
severe disease is seen in children, elderly and immunocompromised individuals. In 
some cases, C. jejuni infection can result in severe sequelae including Guillain–Barre 
syndrome (GBS) (57), relapse of inflammatory bowel diseases (58), reactive arthritis 
(59), and post-infectious irritable bowel syndrome (60).  
 
Because there are no well-established laboratory animal models to study C. jejuni 
infection, the pathogenesis of campylobacteriosis and the contribution of virulence 
factors are incompletely understood. Murine models of C. jejuni are considered 
“colonization” models and lack clinical signs or intestinal lesions unless major 
alterations in inflammatory or immune functions are genetically engineered (61-71). 
IL-10-/- and SCID mice have been utilized to investigate C. jejuni colonization, 
inflammation, and infection, but bacterial colonization and disease varies widely with 
different C. jejuni strains (66, 72, 73). In contrast, animal models in which C. jejuni 
produces clinical disease and intestinal lesions such as dogs (74), ferrets (75-77), 
hamsters (78), one-day-old chicks (79-82), colostrum-deprived neonatal piglets (81, 
83, 84),  and non-human primates (85) are limited by the need for extensive surgical, 
chemical or genetic manipulations, immaturity or lack of research reagents.  
The most studied factors of C. jejuni involved in bacterial colonization and virulence 
are flagella-mediated motility, fibronectin-binding outer membrane protein (CadF), 
Campylobacter invasive antigens (Cia), surface-exposed lipoprotein JlpA, 
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lipooligosaccharide (LOS) and cytolethal distending toxin (CDT) (86, 87). On the 
basis of C. jejuni complete genome sequencing analysis, CDT is the only toxin present 
(88). A PCR-based virulence factor prevalence investigation shows that cdt genes are 
present in 97.5% of C. jejuni strains isolated from diarrheal patients in Bangladesh 
(89). In C. jejuni, CDT does not appear to be secreted, but associated with the bacterial 
cell membrane (90). In vitro experiments show that outer membrane vesicles (OMVs) 
are the potential mechanism of CDT delivery to host cells (91). In vitro, CjejCDT 
induces cell distension and cell cycle arrest in several mammalian cell lines (92, 93). 
Nearly all studies about the role of CDT in disease have focused on in vitro models of 
eukaryotic cell genotoxicity characterized by cell cycle arrest and apoptotic cell death 
(94). CdtB mutant C. jejuni has impaired ability to invade SCID mice compared with 
isogenic wild type strain (68). C. jejuni with disrupted CdtB gene is less efficient in 
adherence and invasion of Hela cells in vitro than isogenic wild type strain (95). When 
inoculated into conventional and IL-10–/– deficient mice, H. hepaticus CdtB-negative 
mutants fail to establish a persistent infection when compared with wild-type parent 
strain (36, 96). These few studies in laboratory mice, mostly with H. hepaticus (36, 37, 
96), but also C. jejuni (64), and others (97, 98) suggest a role for CDT in virulence, 
but the role of CDT in C. jejuni infection remains poorly understood. 
 
Neutrophil extracellular traps (NETs) 
 
Polymorphonuclear neutrophils (PMNs) play a central role as the first line of host 
innate immune defense against microbial infections (99). A novel mechanism of 
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microbial killing that involves de-condensation of PMN’s nuclear chromatin leading 
to extracellular release of DNA and formation of web-like structures was first 
described by Brinkmann and coworkers in 2004 (100). Because extracellular DNA 
fibers and histones decorated with antimicrobial proteins efficiently trap and kill 
microbes, this process was called Neutrophil Extracellular Traps (NETs) (100). Soon 
after that, this process was found in other cells involved in innate defense including 
eosinophils, mast cells and macrophages (101-103). Because this process involves cell 
death by a mechanism different from apoptosis and necrosis, it has been referred to as 
ETosis and NETosis when referring to neutrophils (104). PMNs from diverse 
vertebrate species, including human, mouse, cat, cow, chicken and zebra fish have 
now been shown to form NETs (105-109). Except for neutrophil phagocytosis and 
release of ROS, NETosis is now recognized as a major defense mechanism for capture 
and/or killing of not only bacteria, but also fungi and protozoan parasites (110-114). A 
deficiency in NET formation has now been shown to account for increased 
susceptibility of human infants to microbial infections (115). Under certain 
circumstances NETs can also be detrimental. Excessive or persistent release of DNA 
and granule proteins from NETs has been implicated in development of certain 
autoimmune disorders such as systemic lupus erythematosus (116) and small-vessel 
vasculitis (117), but also contributes to disease progression in bacterial sepsis (118).  
 
Multiple stimuli induce NET formation, including chemokines, cytokines, bacteria and 
their components, viruses and protozoa and many other microorganisms (119, 120). 
Microorganisms induce NETs formation and most of them are trapped and/or killed by 
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NETs. For example, Staphylococcus aureus, Mycobacterium tuberculosis, Escherichia 
coli (100, 106, 121), Toxoplasma gondii and Candida albicans (111, 122) can trigger 
NET formation and are also killed by NETs. Group A Streptococcus  resist killing by 
NETs through secretion of a DNase-Sda1 that destroys NETs’ backbone DNA and M1 
protein to inhibit cathelicidin activity (123, 124). Secretion of nuclease by 
Staphylococcus aureus degradea NETs and their survivability in NETs is much higher 
than nuclease-deficient mutant (125). In addition, phorbol myristate acetate (PMA), 
IL-8, LPS, hydrogen peroxide (H2O2) and interferon induce NETs formation (126), 
but among them, PMA appears to be the most potent inducer of NET formation by 
human peripheral blood neutrophils, and is therefore widely used in NETosis study. 
So far, the signaling mechanisms regulating NET formation are incompletely 
understood. PMNs from patients with inherited chronic granulomatous disease (CGD), 
which involves a mutation in a gene encoding NADPH are incapable of generating 
reactive oxygen species (ROS). PMNs from CGD patients lack the ability to form 
NETs, suggesting ROS is required for NETosis (127). Rac2, a small GTPase involved 
in regulation of ROS generation is also essential for NET formation (128). Moreover, 
peptidylarginine deiminase 4 (PAD4) was shown to be associated with the initiation of 
nuclear chromatin de-condensation and appears to be important in NETosis (129). 
PMNs from individuals deficient in myeloperoxidase (MPO) fail to form NETs (130), 
and genetically engineered neutrophil elastase (NE) knockout mice do not form NETs 
in a pulmonary model of Klebsiella pneumoniae infection (131). This data indicate 
that MPO and NE are also required for NET formation. In the PMA-induced NETosis, 
autophagy or superoxide is involved in intracellular chromatin de-condensation, and 
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inhibition of either of them prevents NETosis (132). Recently, c-Raf kinase and MEK 
inhibitors were found to inhibit PMA-induced NET formation, providing indirect 
evidence that Raf-MEK-ERK pathway contributes to NETosis (133, 134). The most 
recent novel discovery shows that NETosing PMNs, which have intact cell membrane, 
but carry de-condensed ruptured nuclei, are still able to chase bacteria and execute 
their phagocytic function (135). In general, NETosis appears to be a dynamic process, 
and sequential dissection of this process will reveal fundamental mechanisms of NET 
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CAMPYLOBACTER JEJUNI ARE CAPTURED, BUT NOT KILLED BY 





The acute stage of intestinal infection by C. jejuni is characterized by IL-8-mediated 
transepithelial migration of activated PMNs into the intestinal lumen. To date, studies 
examining the role of PMNs in defense against C. jejuni have focused on phagocytic 
uptake and intracellular killing within phagolysosomes; however, phagocytosis-
independent extracellular bacterial killing by release of nuclear DNA and 
antimicrobial effector molecules, so-called neutrophil extracellular trap (NET) has 
emerged as an important innate host defense mechanism against bacterial pathogens. 
Given that PMNs are critical to host innate defense in C. jejuni infection, we 
hypothesize that nuclease activity of CDT mediates resistance to extracellular killing 
in NETs. First, the clinical relevance of NETs in host defense against C. jejuni 
infection was confirmed in two non-human primates that died of acute 
campylobacteriosis. The mouse and human PMNs together with wild-type C. jejuni 
and isogenic CDT nuclease mutant and complemented strains were used to evaluate 
iteration between NETs and C. jejuni for: (i) induction of NETs formation, (ii) capture 
within NETs, (iii) survival within NETs.  
 
The lack of direct induction of NETs formation by C. jejuni incubated either under 
aerobic or microaerobic conditions suggested that NETs formation in C. jejuni 
infection might be indirectly mediated by components present within the intestinal 
microenvironment. Although C. jejuni were efficiently captured, they were not killed 
within a two hour incubation period. Moreover, the lack of significance differences in 
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NETs’ capture and killing between wild-type and isogenic CDT nuclease mutants 
suggested that CDT does not play a role in free C. jejuni from NETs. Given that 
approximately 50% C. jejuni were captured in NETs, we speculate that NETs might 
prevent C. jejuni from disseminating and invading mucosa. Therefore, we propose that 
within the context of the intestinal tract, NETs provide a novel innate defense 




C. jejuni colonizes the mucus on the surface and crypts of the intestine and following 
epithelial invasion elicits host innate and adaptive immune responses (1-5). Vigorous 
in vitro studies show that C. jejuni CDT stimulates IL-8 secretion in polarized human 
colonic epithelial T84 cells, INT407 cells and many other mammalian cell  lines (6, 7). 
Culture of C. jejuni with human intestinal cell line INT407 or monocytic cell line 
THP-1 increases IL-8 secretion (8, 9). It implicates the recruitment of PMNs is 
probably initiated by the pro-inflammatory cytokines such as IL-8 during C. jejuni 
infection. Three stages of host response have been identified as the basis of 
histological examination of colonic biopsies taken from individuals with spontaneous 
C. jejuni infections (10). Stage I (<5 days.) consists of mucosal inflammation 
dominated by polymorphonuclear neutrophils (PMNs) together with crypt abscesses, 
which corresponds with the onset of bloody diarrhea. Stages II and III (7 to >14 days.) 
show gradual transition to mononuclear cell inflammation and recovery. In the C. 
jejuni infected IL-10-/- mice, PMNs infiltration is found in colon even 12-day  post 
infection, and contribute to the pathogenesis of C jejuni infection (11). Thus, the 
hallmark of acute C. jejuni enterocolitis is intestinal recruitment of PMNs which 




Studies on the role of PMNs in defense against C. jejuni are limited to phagocytic 
uptake and killing by toxic reactive oxygen species, proteolytic enzymes, and 
antimicrobial proteins within phagolysosomes (12). In this study, we investigated the 
interaction of PMNs and PMNs in terms of NETosis, and the role that CDT might play 
as a nuclease in this process by using PMNs isolated from mice bone marrow and 
human peripheral blood. Our finding demonstrates that NETs are formed and capture 
C. jejuni in the intestine during C. jejuni infection in vitro; C. jejuni did not actively 
induce NETs by mouse or human PMNs in vitro; C. jejuni were not killed by NETs in 
2 hour co-incubation with NETs, but a significant amount of C. jejuni was captured by 
NETs; CDT did not seem to free bacteria from NETs trap. NETs might be still an 
important defensive mechanism to control C. jejuni infection by entrapping bacteria. 
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Materials and methods 
 
C. jejuni growth condition  
Three different serum type C. jejuni isolated and serum typed by Dr. Gerald Duhamel 
lab were used in the study including ET46, EB53 and ET26. C. jejuni  were grown and 
maintained on Mueller-Hinton blood agar plates (5% sheep blood, Colorado Serum 
Company, Denver, Colorado) at 37°C in the microaerobic condition generated by 
Pack-MicroAero gas pack (Mitsubishi Gas Chemical America, INC., New York, NY). 
After 3 days, bacteria were harvested by cold PBS, washed and re-suspended with 
RPMI 1640 (Invitrogen, Invitrogen, Grand Island, NY) for further use. 
 
Construction of CDT isogenic mutant strains 
The cdtB genes of C. jejuni strains ET46-36-20, isolated from macaques with 
campylobacteriosis (13) were disrupted to produce ΔcdtB mutants, and strain ET46-
36-20 was complemented with a full-length cdtABC operon. Briefly, for directional 
cloning, the full length cdtABC operon of C. jejuni was amplified by PCR with cdtAF 
and cdtCR oligonucleotides to make pBSIIKS+-cdtABC (Strategen, La Jolla, CA). 
The cdtB gene was disrupted by insertional mutagenesis of a kanamycin resistance 
cassette which can function in both C. jejuni and E. coli, (shuttle vector pRY107, 
kindly provided by Dr. P. Guerry, Enteric Diseases Department, Naval Medical 
Research Center, MD), into a unique EcoRI site of cdtB at position 419 and selection 
with 50 μg/ml of kanamycin. The ET46-36-20 strain with a disrupted cdtB gene was 
complemented with a 2.9-kb fragment encompassing the cdtABC operon amplified by 
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PCR, ligated into pRY111, and selection with 20µg/ml of chloramphenicol. 
Sequencing of the recombinant shuttle vector cdtABC-01 revealed the cdtABC 
transcribed in the same orientation as the lacZ promoter. Complementation of the 
ET46-36-20 strain with a disrupted cdtB gene was accomplished by conjugation with 
E. coli harboring either empty pRY111 or cdtABC-01and selection with 200 g/ml of 
kanamycin and 15 g/ml of chloramphenicol. The constructs have been sequenced and 
immunoblotted to confirm the lost or gain of CDT in bacteria.  
 
Mice 
Female CD-1 mice were purchased from the Charles River (Wilmington, MA) and 
used between 6 and 12 weeks old. Mice were maintained in the Transgenic Mouse 
Core Facility at the Cornell University College of Veterinary Medicine. All animal 
experiments were approved by the Cornell University Institutional Animal Care and 
Use Committee. 
 
Mouse PMN purification 
 In all experiments, mice were injected intraperitoneally (IP) with 1 mL of sterile 5% 
(v/v) thioglycolate (BD Biosciences, San Jose, CA), and PMNs were harvested 18 h 
later for assessment of the kinetics of NET induction and ROS production following 
activation. In each experiment, the activation of bone marrow PMNs were compared 
with that of PMNs obtained from the peritoneal cavity of the same mouse. Briefly, 
bone marrow from both femurs and tibias of a mouse were harvested by lavage with 
PBS, and PMNs were purified by discontinuous Percoll density gradient 
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centrifugation (14). PMNs from the peritoneal cavity of the same mouse were 
harvested by lavage and purification by continuous Percoll density gradient 
centrifugation as previously described (15), and erythrocytes were lysed 
hypertonically. PMNs were re-suspended in RPMI 1640 medium (Invitrogen, Grand 
Island, NY). 
 
Human PMN purification  
PMNs were isolated as described previously (16-18). Briefly, human peripheral blood 
was obtained from healthy blood donors via venipuncture and collected using sterile 
sodium heparin-containing tubes (BD Biosciences, San Jose, CA) after informed 
consent. PMNs were isolated from blood by centrifugation at 480 X g for 50 min at 
23°C in a Marathon 8K centrifuge (Fisher Scientific, Pittsburgh, PA) using 1-StepTM 
Polymorphs (Accurate Chemical & Scientific Corporation, Westbury, NY). This 
centrifugation method creates a density gradient to separate blood into visible layers of 
plasma, mononuclear cells, PMNs, and erythrocytes and platelets. PMNs were 
extracted and washed in Mg2+ and Ca2+ free HBSS, and all remaining red blood cells 
in the suspension were lysed hypotonically. Neutrophils were suspended at a 
concentration of 1.0 x 106 cell/mL in HBSS containing 0.5% HSA, 2mM Ca2+, and 
10mM HEPES (Invitrogen), buffered to pH 7.4.  
 
NET killing and catching assay  
500 ul total number of 5 x 105 mouse or human PMNs were plated into each well of 
24-well plates (Corning, Tewksbury, MA), and then activated with 4uM PMA (Sigma, 
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St. Louis, MO) for 4 h at 37oC in air. Medium was replaced with 300 ul C. jejuni WT, 
KO, Comp or blank medium (control) at MOI about 1:10 in RPMI 1640with 10mg/ml 
cytochlasin D (Sigma, St. Louis, MO). After 700 x g 5 min centrifugation, plates were 
incubated 2 h at 37oC in air or in microaerobic condition. For NET killing assay, after 
2 h incubation 10 U/ml bovine DNase I (ThermoFisher Scientific, Waltham, MA) was 
used to destroy NETs and release bacterial at the end of incubation. Total bacteria in 
the well were diluted serially and plated onto Mueller-Hinton blood agar plates to 
determine CFU.  For NET catching assay, at the end of 2 h incubation, free bacteria in 
the supernatant were removed by washing twice, and then trapped bacteria were freed 
by bovine DNase I for CFU determination. 
 
Immunoblottig 
Mouse or human PMNs plated into 24-well plates were incubated at 37oC in 5% CO2 
and air in control medium or medium containing of appropriate concentrations of 
PMA (Sigma, St. Louis, MO) or C. jejuni isogenic mutant strains. At 5, 15, 30, 60 and 
120 min PMNs were lyzed by RIPA buffer, and protein concentration was determined 
by Bradford Protein Assay kit (Bio-Rad, Hercules, CA). The same amount of proteins 
from different treatments were loaded and separated by SDS-PAGE and transferred 
onto PVDF membrane (Bio-Rad, Hercules, CA) to assess phosphorylated ERK1&2 
and β-actin by using anti p-ERK1&2 (Cell Signaling, Danvers, MA) anti β-actin 
(Sigma, St. Louis, MO) antibodies.  After incubation with HRP-conjugated goat anti-
mouse or goat anti-rabbit IgG (Santa Cruz, Santa Cruz, CA), the bands were 
visualized by using Westernbright ECL western blotting detection kit (Advansta, 
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Formalin-fixed and paraffin-embedded sections of Colons from NENPRC Cotton Top 
Tamarins were stained for detection of C. jejuni and NETs. Briefly, tissue sections 
were de-paraffinized by xylene (Sigma, St. Louis, MO) and rehydrated with 100%, 
95% and 80 % ethanol (Sigma, St. Louis, MO) consecutively, and then were 
autoclaved in fast cycle for 7 min to retrieve the antigen.  After blocking with 5% BSA 
(Sigma, St. Louis, MO) for 30 min, antibody to myeloperoxidase (Abcam, Cambridge, 
MA) and C. jejuni (Abcam, Cambridge, MA) were added onto the tissue section, and 
slides were kept in 4oC overnight. Following three washes, secondary goat anti-mouse 
or rabbit antibodies labeled with Alexa 488 or 550 (Invitrogen, Carlsbad, CA) were 
applied to detect MPO and C. jejuni.  Images were taken by using Zeiss 510 LSM 
confocal microscope. 
 
Fluoresence and immunofluorescence microscopy 
Mouse or human PMNs plated onto round coverslip sitting in 24-well plates were 
incubated for up to 4 h at 37oC in 5% CO2 and in control medium or medium 
containing appropriate concentrations of either PMA (Sigma, St. Louis, MO) or C. 
jejuni isogenic mutant strains. For live cell real time fluorescence staining, at 0, 2, and 
4 h, 500 nM SYTOX green (Invitrogen, Carlsbad, CA) and 10ug/ml Hoechst 33342 
(Invitrogen, Carlsbad, CA) were added into the well, and then coverslips were 
 44 
transferred onto slides with ProLong Gold Antifade mounting fluid (Invitrogen, 
Carlsbad, CA). Fluorescence images were taken immediately after 5 min incubation at 
room temperature by using Zeiss 510 LSM confocal microscope.  For 
immunofluorescence staining, PMNs were fixed with 4% (V/V) paraformaldehyde 
(PFA; Sigma, St. Louis, MO) in PBS, and incubated with antibodies to C. jejuni 
(Accurate Chem. & Scientific Corp., Westbury, NY) or myeloperoxidase (Abcam, 
Cambridge, MA) at 4oC overnight. After application of secondary antibodies to mouse 
or rabbit labeled with Alexa Fluo 488 or 550 (Invitrogen, Carlsbad, CA), coverslips 
were transferred onto slides with ProLong Gold Antifade mounting fluid containing 
DAPI (Invitrogen, Carlsbad, CA). Fluorescence images were taken by using Zeiss 510 
LSM confocal microscope. 
  
NET induction and picogreen based extracellular DNA release determination.  
Measurement of extracellular DNA release was adopted and revised from previous 
publication (19). Mouse or human PMNs plated into 96-well plates were incubated for 
up to 4 h at 37oC in 5% CO2 and in control medium or medium containing appropriate 
concentrations of either PMA (Sigma, St. Louis, MO) or C. jejuni isogenic mutant 
strains. 1% Human serum was added to investigate the role of opsonization in during 
NET formation. And then, plates were centrifuged at 700 x g for 10 min to make a 
close contact of PMNs and bacteria. At the indicated time points, 50ul 500 mU/ml 
micrococcal nuclease (Thermo Scientific, Waltham, MA) was added into each well of 
the plates. After 10 min digestion at 37oC, enzymatic reaction was stopped by adding 
5 mM EDTA (pH 8.0). Plates were spun at 1500 x g for 5 min, and 100 ul supernatant 
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was transferred into a flat-bottom 96-well plate for later extracellular DNA evaluation. 
PMNs and bacteria were lysed with 2% triton x-100 to release the entire nuclear DNA 
for determination of the total amount of PMN and bacteria DNA. After all of the 
supernatant at all of time points were collected, 100 ul diluted Picogreen (Invitrogen, 
Carlsbad, CA) was added into samples, and plates were incubated in dark for 5 min at 
room temperature. Fluorescence intensity was measured with a spectrofluorometer at 






C. jejuni are co-localized with NETs present in the Colonic Lumen of a Monkey 
with Campylobacteriosis. 
Spontaneous C. jejuni infection in New World primates (NWP) is characterized by 
acute watery diarrhea that may contain blood or mucus and enterocolitis with PMNs 
and formation of crypt abscesses similar to Stage I human infection (20). Considering 
the PMN response is the hallmark of the acute C. jejuni infection, we checked the 
existence of NETs in the intestine of monkey infected with C. jejuni, and the possible 
interaction between C. jejuni and NETs. DNA and C. jejuni staining of in Macaque 
monkey colonic tissue section (Figure 1.1A&B) showed that a large amount of C. 
jejuni colonized intestine, and many of them were co-localized with DNA, implicating 
that NETs might be formed to catch C. jejuni in the reality. One of the characteristics 
of NETs is the de-congested DNA decorated PMN granule derived proteins such as 
MPO, elastase, etc. (21). In order to confirm the NET formation, MPO, a PMN marker 
during acute inflammation, was stained to identify NETs in C. jejuni infection. 
Immunofluorescence staining of MPO and C. jejuni in colonic section of monkey with 
acute C. jejuni infection showed MPO staining was almost all over intestinal content 
in the intestinal lumen of C. jejuni infected monkey (Figure 1.1C). It indicates a large 
volume of PMNs had infiltrated the intestinal lumen during the acute C. jejuni 
infection. Interestingly, NET like DNA and MPO staining structures were visualized 
in Figure 1.1 C and D, and close-up view of the NETs (pointed by arrow in Figure 1.1 
D) exhibited the co-localized staining of a group of C. jejuni, presumably captured by 
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NETs. However, in the intestine without MPO staining, no NET like structure of 
either DNA was observed (Figure 1.1E).  The existence NET structure together with 
its co-localization with C. jejuni provided direct evidence that NETs were formed in 
the intestinal lumen during C. jejuni infection, and was able to capture C. jejuni.  
 
C. jejuni do not induce mouse or human NET formation. 
Since several bacteria are able to induce NET fromation in vitro (22), but  this has not 
been investigated with C. jejuni. We asked whether or not C. jejuni induce PMNs to 
form NETs, and whether or not C. jejuni CDT interferes with NET formation.  PMNs 
used in the experiments were purified from human peripheral blood and mouse bone 
marrow, and the purity was greater than 90% (Figure 1.2).  After PMNs were 
incubated in the presence of with wild-type (WT) and isogenic C. jejuni mutant strains 
with inactivated CDT (KO) or KO strain complemented with CDT gene (Comp), 
extracellular DNA release was evaluated by picogreen assay. PMN viability and NETs 
formation was visualized by double fluorescence staining with CYTOX green (a cell 
membrane non-permeable DNA dye; extracellular DNA staining) and Hoechst 33342 
(cell membrane permeable dye; total DNA staining).  Although PMA-activated mouse 
PMNs released extracellular DNA, incubation with C. jejuni WT, KO or Comp strains 
did not show significant release of nuclear DNA when compared with untreated 
control PMNs (Figure 1.3A). Double-fluorescence staining with Hoechst33342 and 
SYTOX green showed that a majority of PMNs remained alive after 4 hour co-
incubated with C. jejuni (Figure 1.3B). There were some (<5%) spontaneous NETs 
formed by PMNs either in control or in C. jejuni infected (Figure 1.3B). Activation of 
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ERK1&2 pathway is required for bacterial and PMA-induced NET formation (23). To 
further confirm the lack of NETs induction by C. jejuni, ERK1&2 activation was 
assessed by immunoblotting of the whole cell lysate from PMNs activated by PMA 
and PMNs co-incubated with C. jejuni WT and KO strains over time. Phosphorylated 
ERK1&2 were detected within 5 min in the PMNs stimulated with PMA, but not 
detected in the PMNs co-incubation with C. jejuni WT or KO up to 120 min, which 
was similar to the control non-activated PMNs (Figure 1.3C). Taken together, these 
data suggest that unlike other bacteria, C. jejuni do not induce NET formation in vitro, 
and CDT does not seem to induce any PMN death. 
 
To rule out the possibility that the lack of DNA release is unique to mouse PMNs, we 
examined human NET induction. There was no significant NET release and ERK 
activation (Figure 1.4A&B) detected in human PMNs infected with C. jejuni. The lack 
of NETs induction by C. jejuni with human PMNs and mouse PMNs confirmed that 
C. jejuni do not induce NETs in vitro. Given that C. jejuni is a strict microaerophile 
(156), environmental stress factors intend to affect C. jejuni survival and virulence 
(24). We evaluated the human PMNs NET formation under microaerobic condition, 
which is the actual condition that C. jejuni face during infection. No significant 
extracellular DNA release was detected among PMNs stimulated with different C. 
jejuni strains (Figure 1.4C). Fluorescence staining showed, even though there were 
few spontaneously NETs formed, almost all PMNs in control and C. jejuni infected 
groups remained alive and kept intact cell membrane (Figure 1.4G). However, nearly 
all PMNs treated with PMA lost their membrane integrity; their nuclear chromatin 
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DNA de-condensed and extruded outside. (Figure 1.4G). The lack of inducing NET 
formation brings out one direct question is whether or not C. jejuni inhibit NET 
formation. Under microaerobic condition, human PMNs were pre-incubated with C. 
jejuni for 2 h for a full settlement between C. jejuni and PMNs, and then stimulated 
with PMA for another 4 h. After 4 h PMA activation, human PMNs in presence of C. 
jejuni formed the same amount of NETs as non-treated control PMNs (Figure 1.4D). 
Fluorescence staining confirmed that regardless of the presence of C. jejuni, similar 
amount of NETs was formed after PMA activation (Figure 1.4H); there were no 
differences in NETs formation, observed among the groups of human PMNs co-
incubated with PMA and different C. jejuni CDT isogenic strains (Figure 1.4H). All of 
the three different serum type C. jejuni ET46, EB53 and ET26 did not induce 
significant human NET formation with or without 1% human serum (Figure 1.4E&F), 
implicating all the C. jejuni strains might not be potent NET inducer, and serum 
opsonization does not promote NET formation. It suggests C. jejuni do not inhibit 
PMA-induced human NET formation in vitro. These results demonstrate that C. jejuni 
neither induce human NET formation nor inhibit human NET formation in vitro; CDT 
does not appear to interfere with NET formation. 
 
C. jejuni are captured by NETs, and CDT does not free bacterial from NETs 
capture. 
Since C. jejuni were captured by NETs during C. jejuni infection in vivo, we wondered 
if C. jejuni could be captured in vitro. Mouse PMNs were incubated with PMA for 4 h 
to obtain mouse NETs, and then C. jejuni WT, KO and Comp were added onto NETs. 
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After bacteria free in the supernatant were washed away, immunofluorescence was 
performed to detect NETs and C. jejuni. As shown in Figure 1.5, C. jejuni WT, KO 
and Comp were entrapped in the NETs, and bacteria staining co-localized with the 
track of NETs. When NETs were dismantled by bovine DNase I, only nucleus from 
intact PMNs were left, and no bacteria were seen (Figure 1.5). Generally, NETs are 
capable of capturing C. jejuni.  
 
We next checked the efficacy of NET capture and whether or not CDT could free 
bacteria from NETs capture by digesting NETs in terms of its nuclease activity. Under 
microaerobic condition, approximately 50% of C. jejuni WT, KO and Comp inoculum 
was captured by human NETs (Figure 1.6A). Nearly all of the C. jejuni were released 
after NETs were dismantled by bovine DNase I (Figure 1.6A). Immunofluorescence 
images in 63x magnification clearly showed that C. jejuni were entrapped by NETs 
(Figure 1.6B). However, the percentages of NET captured bacteria among C. jejuni 
WT, KO and Comp isogenic strains were not significant different (Figure 1.6A), 
demonstrating that CDT might not contribute to fighting against NET entrapment.  In 
sum, approximately half of the C. jejuni were trapped by NETs; however C. jejuni 
CDT did not free bacteria from NET capture I our in vitro experiments.  
 
NETs do not exert efficient extracellular killing of C. jejun in vitro. 
C. jejuni are captured by NETs, and we assessed the ability of NETs to exert killing of 
C. jejuni and whether or not CDT contributes to bacterial survival. C. jejuni WT, KO 
and Comp were added onto NETs made from PMA induced mouse or human PMNs. 
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After 2 h co-incubation with NETs in either aerobic or microaerobic condition, total 
number of C. jejuni was determined by CFU assay. Interestingly, in aerobic condition 
no CFU was seen in neither of the three C. jejuni isogenic strains that were left in the 
blank medium without NETs (Data not shown), but not the C. jejuni incubated with 
NETs; however, C. jejuni in the blank medium under microaerobic condition retained 
similar amount of CFU as inoculum. It indicates microaerobic condition is critical for 
C. jejuni, and C. jejuni may take advantage of NETs to survive in aerobic condition 
(Figure 1.7 D-I).  No significant numbers of CFU were found between inoculum and 
bacteria treated with NETs among all three C. jejuni CDT isogenic strains (Figure 
1.7A-I). These results suggest C. jejuni were not killed by NETs in vitro, and C. jejuni 








Figure 1.1. C. jejuni trapped in NETs within the colonic lumen of a Macaque with 
campylobacterioisis. Double-staining and merged confocal laser scanning 
microscopy images  of colon from a macaque monkey with naturally-occurring acute 
colitis associated with C. jejuni infection shows large numbers of C. jejuni (green) 
along the colonic surface epithelium (A, arrows). Close up view of the boxed area in A 
with C. jejuni (green) trapped within large aggregates of luminal extracellular DNA 
(red) (B). Colonic tissue section of a Tamarin monkey with naturally-occurring acute 
colitis associated with C. jejuni infection was stained for detection of C. jejuni (red) 
MPO (green) and DNA (blue) (C). Close-up view of the boxed area in (C) with C. 
jejuni (red) trapped within large aggregates of luminal extracellular DNA (blue) and 
MPO (green) (D). (40X original magnification). Colonic tissue section of a Tamarin 
monkey with C. jejuni infection (without PMN infiltration) was stained for detection 















Figure 1.2 Purified thioglycolate-elicited mouse bone marrow and human 
peripheral blood derived PMNs. Photomicrographs of thioglycolate-elicited mouse 
bone marrow derived PMNs (A) harvested 18 h after intraperitoneal injection with 5% 
(v/v) thioglycolate medium to elicit sterile inflammation. (B) Human PMNs were 
purified from peripheral blood. Greater than 90% PMNs are obtained from mouse and 





Figure 1.3 C. jejuni do not induce mouse NETs in vitro. The percent extracellular 
DNA release by non-activated BMDM-PMNs (negative control) and PMA-activated 
PMNs (1µM PMA; positive control) was compared with that of PMNs incubated with 
C. jejuni WT, KO or Comp strains for up to 4 h at 37oC in air (A). At the end of the 
incubation period, extracellular DNA was digested with monococcal nuclease (500 
mU/mL final concentration) for 10 min at 37oC, and the percent DNA release was 
quantified by using a Picogreen Assay. Data are expressed as percent total DNA 
release from TritonX100 lyzed PMNs. (B) Double immunofluorescence LCFM image 
of extracellular DNA release from non-activated BMDM-PMNs (negative control) and 
PMA-activated PMNs (1µM PMA; positive control) compared with PMNs incubated 
in the presence of C. jejuni WT and KO strains for 4 h at 37oC in air and stained with 
Hoechst33342 (Hoechst) and SYTOX Green. (C) BMDM-PMNs obtained from 
control and samples incubated in the presence of PMA or of C. jejuni WT and KO 
strains for 5, 15, 30, 60 and 120 min were lyzed and phosphorylated ERK1&2 and β-
actin were assessed in immunoblotting assay by using anti p-ERK1&2 antibody. Each 
experiment was done in triplicate, and representative data from two independent 












Figure 1.4 C. jejuni do not induce human NETs in vitro either in air or 
microaerobic condition, and do not inhibit PMA-induced NET formation. The 
percent extracellular DNA release by non-activated human PMNs (negative control) 
and PMA-activated PMNs (200nM PMA; positive control) was compared with that of 
PMNs incubated with C. jejuni WT, KO or Comp strains at MOI of 100:1 for up to 4 h 
at 37oC in air. (A) At the end of the incubation period, extracellular DNA was digested 
with monococcal nuclease (500 mU/mL final concentration) for 10 min at 37oC and 
the percent DNA release was quantified by using a Picogreen Assay. (B) Human 
PMNs obtained from control and samples co-incubated with PMA or C. jejuni WT 
and KO strains for 5, 15, 30, 60 min were lysed and phosphorylated ERK1&2 and β-
actin were assessed in immunoblotting assay by using anti p-ERK1&2 antibody. (C & 
G) The same treatment was set up as described in (A), but activation was performed at 
37oC in microaerobic condition. Double immunofluorescence LCFM image of 
extracellular DNA release stained with Hoechst33342 (Hoechst), and SYTOX Green 
was taken at 20 x magnification by Zeiss 510 laser scanning confocal microscope. (D) 
Human PMNs were pre-infected by C. jejuni WT, KO or Comp strains at MOI of 
100:1 for 2h at 37oC in microaerobic condition, and then 200nM PMA was added to 
the non-C. jejuni infected PMNs and control human PMNs. After 4 h incubation at 
37oC microaerobically, the percent extracellular DNA release was quantified by 
Picogreen assay. (E&F) Human PMNs were co-incubated with other two different 
serum type of C. jejuni EB53 & ET26 together with ET46 in the presence of 1% 
human serum or without human serum. Extracellular DNA release was evaluated as 
described above.  (H) After human PMNs were plated onto coverslips sitting in 24-
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well plates, they were pre-treated with C. jejuni, and then activated with PMA 
consequently. PMNs were stained with Hoechst 33342 and SYTOX Green 4 h post 
treatment. Immunofluorescence images were taken at 20 x magnification by Zeiss 510 
laser scanning confocal microscope. Each experiment was done in triplicate, and 
representative data from two independent experiments is shown (Error bars represent 























Figure 1.5 C. jejuni WT, KO and Comp were captured by mouse NETs. NETs 
from PMA-activated BMDM-PMNs were incubated with medium or medium 
containing either C.jejuni (WT), KO or Comp for 1 h (MOI 100:1).  At the end of the 
incubation period, control NETs were digested for 15 min by adding bovine DNase I 
(10 U/ml final concentration) before removing free bacteria in the culture supernatant 
by washing, fixation with 4% paraformaldehyde and double-immunofluorescence 
staining LCFM. Extracellular DNA was stained with SYTOX Green, nuclear DNA 
was stained with Hoechst 33342 and C. jejuni with affinity purified rabbit polyclonal 
IgG to C. jejuni followed by Alexa Fluor (555; red) goat anti-rabbit IgG. 20X original 
magnification images captured with an inverted confocal laser scanning microscope 





Figure 1.6 C. jejuni are captured by human NETs and CDT does not mediate 
bacterial escape from human NETs. (A) Following PMA activation of human 
PMNs and treatment with cytochalasin D to inhibit phagocytic uptake, NETs were 
removed by using bovine DNase I digestion after incubation with C. jejuni WT, KO, 
or Comp strains (MOI 1:1). After 1 h co-incubation at 37oC in microaerobic condition, 
free bacteria in the culture supernatant were removed by washing, and the numbers of 
live bacteria associated with NETs were expressed as a percentage of the inoculum. 
(B) Following 4 h PMA activation of human PMNs plated onto coverslips in 24-well 
plates, PMNs were treated with cytochalasin D to inhibit phagocytic uptake. C. jejuni 
WT, KO, or Comp strains (MOI 100:1) were added onto human NETs. After 1 h 
incubation at 37oC in microaerobic condition, free bacteria in the supernatant were 
removed by 3 washes. C. jejuni alone were fixed onto coverslip without PMNs for 
determination of the MPO antibody specificity. Immunofluorescence was performed 
to detect C. jejuni and MPO. DNA was stained with DAPI. (40x magnification). Each 
experiment was done in triplicate, and representative data from three independent 
































Figure 1.7 Mouse and human NETs do not kill C. jejuni WT, KO, and Comp 
strains. NETs obtained from PMA-activated BMDM-PMNs and human PMNs for 4 h 
were pre-treated with fresh medium containing cytochalasin D (10 µg/mL) to inhibit 
phagocytosis, and then incubated with C. jejuni CDT isogenic strains (MOI 1:1). After 
2 h incubation at 37oC in aerobic condition (A, B and C) or in microaerobic condition 
(D, E, F, G, H, I), C. jejuni were plated onto sheep blood agar plates to determine 
bacteria CFUs. No CFUs were detected in the control C. jejuni that were incubated in 
the aerobic condition. Each experiment was done in triplicate, and graphs are 
representative of three independent experiments. (Error bars represent Mean±SEM; 




















In this study, we discovered NETs in the intestinal lumen of monkey with C. jejuni 
infection, and C. jejuni were captured in NETs. We found that PMNs, recruited to the 
C. jejuni infected intesine, make NETs to control C. jejuni infection. In vitro, C. jejuni 
do not appear to induce NET formation; C. jejuni are largely captured by NETs, but 
manage to survive in NET capture; CDT does not seem to play a role in NET 
induction and releasing bacteria from capture. NETs might be an import mechanism to 
control C. jejuni infection by entrapping C. jejuni, and C. jejuni are able to avoid 
NETs killing by unknown mechanism. 
 
Several bacteria have been reported to induce NET formation such as E. coli and 
Shigella flexneri (22, 25). However, C. jejuni did not induce mouse NET formation in 
vitro. Considering C. jejuni are strict microaerophile, and experiments were also 
performed under micoaerobic condition to favor C. jejuni living. No matter in aerobic 
or in microaerobic condition, C. jejuni did not induce human NET formation. ERK1/2 
activation appears to be essential in NET formation. Inhibition of ERK1/2 by chemical 
inhibitors blocks NETs formation mediated by PMA (23, 26) and Toxoplasma gondii 
(15). Non-activation of ERK1/2 observed in the PMNs treated with C. jejuni 
confirmed that C. jejuni do not induce NET formation in our in vitro experiment. The 
fact that two other different type C. jejuni strains EB53 and ET26 do not induce NETs 
implicates that it might be common that C. jejuni do not induce NET formation in a 
wide range of this specie. The lack of PMN response to C. jejuni may result from the 
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maturity of the purified PMNs. Mouse bone marrow PMNs are in a resting state and 
have the capacity to become primed, while peritoneal exudate PMNs are already 
mature upon isolation. Peritoneal exudate PMNs generate more reactive oxygen 
species upon stimulation that bone marrow PMNs (27). Maturation of PMNs looks to 
be associated with transcellular migration, progressive starvation or sequential shifts in 
quantity and quality of tissue factors, chemokines and pro-inflammatory cytokines 
along their migration to the infection site. During C. jejuni infection in vivo, PMNs 
recruited into the intestinal lumen may be more mature than PMNs in bone marrow or 
peripheral blood derived PMNs in vitro. Even though C. jejuni do not induce NET 
formation, PMNs in the intestine might be more sensitive and intend to make NETs 
under the pressure from gut flora and contents, which are known as NET inducers. 
 
One major function of NETs is to capture and kill microorganism (28, 29). Our Data 
show that more than 50% of C. jejuni was trapped in NETs. Group A Streptococcus 
resist NETs killing by secreting DNase-Sda1 to destroy NETs’ backbone DNA and 
M1 protein to inhibit cathelicidin activity (30, 31). Staphylococcus aureus secret a 
nuclease to degrade NETs, and their survivability in NETs is much higher than 
nuclease-deficient mutant (32). The CdtB subunit of CDT has nuclease activity, and 
can digest plasmid DNA in vitro (33). However, no significant difference observed 
among CjWT, CjKO and CjComp strains in NET catching assay suggests that CDT is 
not able free bacteria from capture by digesting NETs. Several of the CDT properties 
may explain this observation. First, Staphylococcus aureus nuclease can digest DNA 
completely in a short time (32). However, CDT nuclease activity is much lower than 
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bovine DNase I. In vitro 6 h digestion with CdtB only cut a small portion of plasmid 
DNA open, and do not generate DNA smear (33). CDT may not be powerful enough 
to digest NET DNA, or it may require a fairly long period of time to digest NET DNA. 
Elongation of incubation time with NETs may help CjejCDT fully execute its nuclease 
function. However, due to the limitation of in vitro assay, our NET catching remained 
in 2 h incubation. Second, that CjejCDT is not detectable in the culture supernatant by 
immunoblotting, but present in the enriched bacterial cell membrane (7) infers C. 
jejuni CDT not only appears to be cell membrane associated, but also its abundance on 
the bacteria membrane is extremely low. Last, the association of PMN granule 
proteins with chromatin DNA may hamper CDT from reaching DNA. Generally, it 
suggests CDT does not seem to have the capacity to free bacteria from NET capture. 
That C. jejuni were captured and fully contacted with NETs in confocal microscopy 
means C. jejuni were under attack from the all bactericidal proteins on the NETs. 
However, C. jejuni were not killed in 2 h co-incubation with NETs in either aerobic or 
microaerobic condition. Genome wide analysis indicates that C. jejuni has no obvious 
homologues to the known virulence factors from other bacterial pathogens (34). 
Understanding of C. jejuni pathogenicity is still an ongoing effort, and the strategy that 
C. jejuni utilize to escape from NET killing needs more investigation.    
 
In sum, NETs were visualized to trap C. jejuni in the infected intestine. C. jejuni were 
captured within NETs; however, bacterial killing was inefficient and C. jejuni CDT 
did not contribute to escape of bacteria from NETs in vitro.  NETs might play an 
essential role in preventing C. jejuni from disseminating by entrapping bacteria; 
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eventually, the trapped bacteria may be evacuated by the host intestinal peristalsis and 
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THE CYTOLETHAL DISTENDING TOXINS OF HELICOBACTER HEPATICUS 
AND CAMPYLOBACTER JEJUNI INDUCE PREMATURE SENESCENCE OF 





Premature cellular senescence refers to the non-aging related cellular senescence. The 
hallmark of premature senescence is permanent arrest of cell proliferation, while 
remaining metabolically active. Cellular senescence is thought to be an anti-cancer 
mechanism, and has been studied mostly within the context of aging, DNA damage 
and oncogene-induced senescence. However, little is known about the contribution of 
premature senescence in infectious diseases. Cytolethal distending toxin, a genotoxin 
involved in bacterial persistent infection, is an AB type toxin composed of three 
subunits (CdtA, CdtB and CdtC). Helicobacter hepaticus (H. hepaticus) and 
Campylobacter jejuni (C. jejuni) cytolethal distending toxins cause DNA damage, 
induce cell cycle arrest, mediate apoptosis, and stimulate pro-inflammatory cytokine 
IL-6 and IL-8 secretion in vitro. Given that persistent DNA damage promotes cellular 
senescence, we hypothesized that a sub-lethal concentration of H. hepaticus CDT 
(HhepCDT) or C. jejuni CDT (CjejCDT) or C. jejuni whole cell lysate (WCL) induce 
premature cellular senescence and pro-inflammatory cytokine production by intestinal 
epithelial cells. 
 
To investigate CDT genotoxicity we used C. jejuni wild-type strain (CjejWT) along 
with isogenic C. jejuni strains with disrupted CDT gene (CjejKO) and C. jejuni KO 
complemented with CDT gene (CjejComp) as well as recombinant HhepCDT and 
CjejCDT. After 7-day intoxication, a significant number of HhepCDT, CjejCDT, 
CjejWT and CjejComp WCL treated epithelial INT407 cells were arrested at G2/M 
 79 
phase of the cell cycle and showed a persistent DNA damage response (DDR). 
Consistent with this observation was positive staining for the presence of senescence-
associated beta-galactosidase activity, and elevated mRNA and expression of IL-6 and 
IL-8 proteins. These features are consistent with CDT-induced premature cellular 
senescence. In addition, the anti-tumor and anti-inflammatory cytokine IL-24 was also 
up-regulated in intoxicated INT407 cells. Consistent with a very potent genotoxin, 
only 400 ng/mL C. jejuni WCL was required to induce cellular senescence, while 20 
ug/mL was required for recombinant CDT. In conclusion, the data suggest that 
premature cellular senescence might be an important host defense mechanism against 




The phenomenon of cellular senescence was first described in the observation of 
infinite human diploid cell proliferation, and these cells eventually exit cell cycle 
irreversibly, but still remain alive metabolically (1). Cellular senescence is a 
preventive response to cease the proliferation of damaged cells. Substantial evidence 
shows that it is an anti-cancer mechanism (2-4).Cellular senescence is commonly seen 
in aging cells, and can also be induced by other cellular stresses such as DNA damage 
and oncogenic activation triggered by mutation (5-8). DNA damage response (DDR) 
is a very common element to induce cellular senescence (7). In order to differentiate it 
from the cellular senescence caused by the shortening of telomere in aging, senescence 
induced by other factors is termed as premature cellular senescence (9).   
 
Senescent cells display several features (10, 11) including: (i) irreversible cell growth 
arrest while remaining metabolically active, (ii) up regulation of senescence associated 
β-galactosidase expression, which can be detected by histochemical staining at pH 6.0; 
(iii) changes in gene expression pattern, including  upregulation of cell-cycle 
inhibitors p16 and p21; (iv) secretion of IL-6 and IL-8 so called senescence-associated 
secretory phenotype (SASP); (v) presence of senescence-associated DNA-damage 
foci. All the characteristics of cellular senescence may not be strictly  relevant to every 
senescent phenotype, but three or more markers together with the morphological 
change can be a bona fide way to detect senescent cells (12).  
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Cellular senescence has been intensively studied in aging, DNA damage and oncogene 
induced senescence (10). However, less is known about the contribution of premature 
senescence in infectious diseases. A potent genotoxin cytolethal distending toxin 
(CDT) produced by about two dozen of bacterial species such as Escherichia coli, 
Helicobacter hepeticu (H. hepaticus), Salmonella enterica and Campylobacter jejuni 
(C. jejuni) is known to cause DDR and induce cell cycle arrest (reviewed in 37). Here 
we utilize H. hepaticus and C. jejuni CDT (CjejCDT) to investigate the potential role 
of CDT in inducing cellular senescence in vitro. CDT is found to be the only toxin 
present in C. jejuni when the complete genome sequencing analysis is accomplished 
(13). A PCR-based virulence factor prevalence investigation shows that the presence 
of cdt genes is 97.5% in C. jejuni species identified from diarrheal patients in 
Bangladesh (14).  
 
C. jejuni CDT does not appear to be detected in the culture supernatant by 
immunoblotting, but it can be detected in the enriched bacterial cell membrane (15). In 
vitro, experiment shows that outer membrane vesicles (OMVs) are the potential vector 
that delivers CDT into the host cells and the surrounding environment (16). C. jejuni 
recombinant CDT induces typical cell distension and cell cycle arrest in different 
mammalian cell lines in vitro (17, 18). CdtB mutant C. jejuni has an impaired ability 
to invade SCID mice compared with the wild type strain (19). CdtB mutant C. jejuni is 
able to colonize NF-kB deficient mice, but does not induce gastroenteritis (20). C. 
jejuni with disrupted CdtB gene is less efficient in adherence and invasion to Hela 
cells in vitro than C. jejuni wild type strain (21). This implicates CjejCDT contributes 
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to bacteria invasion and colonization. The formation of γ-H2AX, a marker of DDR 
response, seen in Hela cells intoxicated with Haemophilus ducreyi CDT (22), INT407 
cells exposed to H. hepaticus CDT (23) and fibroblasts treated with CjejCDT (24) 
suggests that CDT causes DNA damage and triggers DNA repair machinery. Direct 
consequences of DDR are cell distension and cell cycle arrest. CjejCDT causes G2/M 
cell cycle arrest in fibroblasts by promoting DDR (18, 24). Except for initiating DDR 
and cell cycle arrest, CjejCDT is reported to stimulate IL-8 secretion in polarized 
human colonic epithelial T84 cells and INT407 cells (15, 25). IL-8 is a pro-
inflammatory cytokine that recruits neutrophils to the infection sites, and neutrophil 
infiltration is a hall mark of acute C. jejuni enterocolitis (26, 27), and it implies that 
CDT may be involved in the host immune response against C. jejuni infection. 
 
Recently, it is reported that fibroblasts or colon epithelial cells exposed to continuous 
sub-lethal recombinant Helicobacter ducreyi CDT  stimulation over several weeks 
showed greater frequency of genomic instability (28). Interestingly, CDT from Shiga 
toxin-producing E. coli O157 induces G2/M cell cycle arrest of human endothelial 
cells for up to 5 days, a feature indicative of cellular senescence (29, 30). CjejCDT 
causes epithelial cell distension and cycle arrest, and stimulates IL-8 expression, 
which is one of the SASP (15). Given that CDT cytotoxicities described above are also 
typical characteristics seen in senescent cells, we hypothesized that HhepCDT and 
CjejCDT will cause intestinal epithelial cells senescence if intoxicated long term.  
 
 83 
Our study shows that human intestinal epithelial INT407 cells treated with sub-lethal 
doses of HhepCDT, CjejCDT, CjejWT WCL and CjejComp WCL display 
characteristic DDR, including arrest of the cell cycle and up regulation of γ-H2AX 
formation, intracytoplasmic accumulation of beta-galactosidase and secretion of 
SASP. However, senescence markers are not observed in HI-HhepCDT, HI-CjejCDT 
and CjejKO WCL treated cells, which look the same as normal cells. Based on 
evidence of these three cellular senescence markers, we can conclude H. hepaticus and 
C. jejuni CDT is a very potent genotoxin that induces cellular senescence in epithelial 
cells in vitro.  
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Materials and methods 
 
C. jejuni growth condition and whole cell lysates preparation 
C. jejuni strain and construction of CdtB isogenic mutants were described in 
supplemental material and methods. C. jejuni ET46-36-20 (CjejWT), C. jejuni ET46-
36-20 CdtB knockout (CjejKO), and C. jejuni ET46-36-20 CdtB knockout 
complemented strain ABC01 (CjejComp) were grown on Mueller-Hinton blood agar 
plates (5% sheep blood, Colorado Serum Company, Denver, Colorado) at 37°C in the 
microaerobic condition generated by Pack-MicroAero gas pack (Mitsubishi Gas 
Chemical America, INC., New York, NY). After 3 days, bacteria were harvested by 
cold PBS, and sonicated to make whole cell lysate (WCL).  WCL was centrifuged at 
4000g for 10 min, and supernatant was collected and filtered through 0.22 um filter 
(Corning, Tewksbury, MA). WCL concentration was determined by using BCA 
Protein Assay Kit (ThermoFisher Scientific, Rockford, IL).  
 
Cell culture conditions 
Human intestinal epithelial INT407 cell line (ATCC CCL-6) was maintained in 
Dulbecco’s modification of Eagle’s minimum essential medium (DMEM; Sigma, St. 
Louis, MO) supplemented with 10% fetal bovine serum (Atlanta Biologicals, 
Norcross, GA) and gentamicin (50 g/ml, Sigma, St. Louis, MO) at 37°C in a 
humidified atmosphere of 5% carbon dioxide in air as previously described (31). Cells 
were harvested by washing with phosphate-buffered saline (PBS; pH 7.4) followed by 
treatment with trypsin (Gibco, Grand Island, NY) at 37°C. For cell proliferation 
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assays, γ-H2AX immunoblot, and cytokine/chemokine determinations, INT407 cells 
were seeded in 24-well flat bottom culture plates (Corning Inc., Corning, NY) 
containing 1 mL of medium for up to 7 days. For determination of β-galactosidase 
expression, INT407 cells were grown on sterile 12 mm diameter round poly-L-lysine 
coated glass coverslips (Bellco Glass, Inc., Vineland, NJ) placed in 24-well flat 
bottom culture plates (Corning Inc.). For flow cytometry analysis, INT407 cells were 
seeded in 6-well flat bottom culture plates (Corning Inc.) containing 2 mL of medium 
for up to 7 days. To avoid cell overgrowth, all wells except those treated with 
HhepCDT were seeded with ten times fewer initial numbers of cells (approximately 1 
x 104/mL in 24-well and 4 x 104/mL in 6-well culture plates). 
 
Cell viability  
Sequential determinations of INT407 cell proliferation was done by using trypan blue 
dye exclusion and a hemocytometer counting chamber (Hausser Scientific, Horsham, 
PA). After washing with PBS and treatment with trypsin, the cells were resuspended 
in DMEM, mixed 1:1 with 0.4% trypan blue solution (Gibco, Grand Island, NY) and 
the total numbers of viable cells were counted immediately. 
 
Reconstituted recombinant H. hepaticus CDT (HhepCDT) and C. jejuni CDT 
(CjejCDT).  
Reconstituted recombinant HhepCDT from H. hepaticus mouse strain 3B1/Hh-1 
(ATCC 51449T, Manassas, VA) (32) was prepared by mixing equal amounts of CdtA 
(HhepCdtA), CdtB (HhepCdtB), and CdtC (HhepCdtC) proteins expressed in 
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Escherichia coli, as previously described (23). Individual or combinations of 
recombinant fusion protein subunits were reconstituted as described previously (33, 
34). Briefly, 20 µg of each recombinant fusion protein subunit was mixed in 100 µl of 
PBS (pH 7.4), and after incubation at 30°C for 1 h, reconstituted HhepCDT complexes 
were added to corresponding wells of 6-well or 24-well plates, followed by co-
incubation for the indicated time. 
 
Individual His-tagged C. jejuni CDT subunits were expressed in E. coli, and CDT 
holotoxin was reconstituted according to previously described protocols for 
Helicobacter hepaticus CDT with modifications (Dassanayake et al., 2005; Liyanage 
et al., 2010). Briefly, the gene sequence encoding each CjejCDT sub-unit was 
amplified by using specific primer pairs (Table 4.2) and high fidelity Pfx DNA 
polymerase (AccuPrime, Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. The amplified products were cloned in the pET-28a(+) expression vector 
(Novagen, Darmstadt, Germany) and transformed into E. coli BL21 (New England 
BioLabs, Ipswich, MA). Expression was induced when cultures grown at 37°C in 
Luria-Bertani medium containing kanamycin (Sigma, St. Louis, MO) reached an 
optical density at 600 nm of 0.6-0.8 by adding 1 mM isopropyl-β-D-
thiogalactopyranoside (Invitrogen, Grand Island, NY) and grown an additional 5 h at 
25°C. CjejCdtA and CjejCdtB were purified under denaturing conditions while CdtC 
was purified under native conditions.  The purity of each recombinant protein 
preparation was determined by SDS-PAGE followed by Coomassie blue staining and 
Western blot as previously described (Dassanayake et al., 2005). The CDT holotoxin 
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was reconstituted as previously described (Liyanage et al., 2010) and stored at -80°C 
in 1:1 sterile glycerol.  For negative controls, reconstituted recombinant CjejCDT was 
heat inactivated (HI) for 10 min at 70°C and stored at -80°C in 1:1 sterile glycerol. 
(The clones were constructed and tested by Dr. Rasika Jinadasa when he was in 
Dr. Duhamel’s laboratory. Since the data are not published yet, the method 
described here was directly adopted from Dr. Rasika Jinadasa Ph.D thesis 
entitled “Molecular mechanisms of cycle arrest and apoptosis in lymphoid cells 
elicited by cytolethal distending toxin, a genotoxin produced by Campylobacter 
jejuni and Helicobacter hepaticus") 
 
Dtermination of sub-lethal dose of HhepCDT, CjejCDT, CjejWT WCL and 
CjejComp WCL to IN407 cell  
Approximately, 1 X 105 INT407 cells were plated into 24-well plates, and treated with 
blank medium (control), HhepCDT, CjejCDT, CjejWT WCL and CjejComp WCL in a 
serial 5 x dilution manner. Each dilution of different protein was plotted in triplicate. 
Cells were checked every day (up to 7 days) for the cell distending toxicity. The 
dilution that did not kill the cells, and also made 100% cells enlarged was determined 
to be the sub-lethal dose to INT407 cells. 
 
INT407 cell intoxication with recombinant proteins and C. jejuni WCL 
Approximately, 1 X 105 or 3 x 105 INT407 cells were seeded into 6-well or 24-well 
plates (Costar, Cambridge, MA, USA) containing 2 ml or 1 ml medium with 20 μg/ml 
HhepCDT, 20 μg/ml CjejCDT, 20 μg/ml heat inactivated CjejCDT (HI-CjejCDT, 
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70oC for 30 min), 20 μg/ml heat inactivated HhepCDT (HI-HhepCDT, 70oC for 30 
min), 400ng/ml CjejWT WCL, 400ng/ml CjejKO WCL, 80ng/ml CjejComp WCL, or 
blank medium (control). Treated INT407 cells were incubated at 37°C in a humidified 
atmosphere of 5% CO2 in air for up to 7 days.  To prepare the recombinant CDT 
holotoxin, individual or combinations of recombinant fusion protein subunits were 
reconstituted as described previously (33, 34). Briefly, 20µg of each recombinant 
fusion protein subunit were mixed in 100µl of PBS (pH 7.4), and after incubation at 
30°C for 1 h, the reconstituted CDT complexes (HhepCDT or CjejCDT) were added 
into corresponding wells of 6-well or 24-well plates, followed by co-incubation for the 
indicated time.  
 
Senescence-associated β-galactosidase staining 
On day 1, 3, 5 and 7 of incubation in the presence of control medium or medium 
containing a sub-lethal concentration of reconstituted recombinant HhepCDT, 
CjejCDT, HI-HehCDT, HI-CjejCDT, CjejWT WCL, CjejKO WCL or CjejComp 
WCL, INT407 cells seeded on coverslips in 24-well plates were fixed with freshly 
made 4% (w/v) paraformaldehyde (PFA) and processed for histochemical detection of 
cytoplasmic β-galactosidase expression at pH 6 according to the manufacturer’s 
instructions (Senescence β-galactosidase Staining Kit; Cell Signaling Technology, 
Danvers, MA). After counterstaining with nuclear fast red stain (Vector Laboratories, 





INT407 cells incubated in the presence of control medium or medium containing an 
either a sub-lethal concentration of reconstituted recombinant HhepCDT CjejCDT or 
the corresponding heat-inactivated HhepCDT (HI-HhepCDT), heat-inactivated 
CjejCDT (HI-CjejCDT), CjejWT WCL, CjejKO WCL, CjejComp WCL or individual 
recombinant HhepCdtA, HhepCdtB, HhepCdtC subunits were harvested day 0, 3, 5 
and 7 incubation and lysed by using RIPA buffer according to the manufacturer 
instructions (Cell Signaling Technology, Beverly, MA). After separation by 
electrophoresis on 12% SDS-polyacrylamide gels, cell proteins were electrotransferred 
onto polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Hercules, CA), and 
Western blotting was done by using mouse monoclonal anti-human histone H2A.X 
phosphorylated at Ser 139 immunoglobulin (Ig) G1 antibody (Clone JBW301; EMD 
Millipore, Billerica, MA). To confirm equal loading of each cell preparation, a mouse 
monoclonal anti-human β-actin IgG1 antibody (Clone AC-15; Sigma, St. Louis, MO) 
was used. Specific protein bands were identified by incubation with horseradish 
peroxidase (HRP)-conjugated polyclonal goat anti-mouse IgG antibody (Santa Cruz, 
Santa Cruz, CA) followed by chemiluminescence detection (WesternBright ECL 
Western Blotting HRP Substrate; Advansta, Menlo Park, CA) and an image capture 
workstation (V3 Western Workflow; Bio-Rad, Hercules, CA). 
 
Immunofluorescence 
INT407 cells treated with CjejWT WCL, CjejKO WCL, CjejComp or blank medium 
were plated in 24-well plates with coverslips (ThermoFisher Scientific, Waltham, 
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MA) sitting on the bottoms of each well. After fixation with 4% PFA at day 1, 3, 5 
and 7, cells were stained for detection of γ-H2AX or p21 by using monoclonal mouse 
anti-γ-H2AX antibody (1:1000 dilution, EMD Millipore, Billerica, MA), or 
monoclonal rabbit anti-human p21 antibody (1:1000 dilution, Cell Signaling 
Technology, Danvers, MA). Alexa-fluo labeled goat anti-mouse or goat anti-rabbit 
secondary antibody (Invotrogen, Grand Island, NY) was used to detect primary 
antibody. Alexa Fluo labeled Phalloidin (Invotrogen, Grand Island, NY) was added 
the same time with secondary antibody to stain actin. DAPI (Invotrogen, Grand Island, 
NY) was applied for DNA counter staining. After staining process, coverslips were 
taken out and mounted with Permount (ThermoFisher Scientific, Waltham, MA), and 
then images were taken at 20 x magnification by Zeiss laser confocal microscopy.  
 
Flow cytometry 
INT407 cells incubated in the presence of control medium or medium containing a 
sub-lethal concentration of reconstituted recombinant HhepCDT, CjejCDT, CjejWT 
WCL, CjejKO WCL, CjejComp WCL or corresponding HI-HhepCDT or HI-CjejCDT 
were harvested on day 0, 1, 3, 5 and 7 and the percent of cells in G0/G1 (green), S 
(blue) and G2/M (red) phases were determined by staining with propidium iodide and 
fluorescent flow cytometry as described previously (31). Briefly, harvested cells were 
transferred to 70% ethanol, held overnight at -200C, followed by rehydration with 1 
mL PBS at room temperature for 15 min, and after centrifugation, were stained with 
propidium iodide (PI). For DNA content determinations, approximately 1.0 X 105 
cells were examined by FACS analysis, with the excitation set at 488 nm and the 
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emission set at 630 nm (BD™ LSR II Flow Cytometer, Becton Dickinson, San Jose, 
CA, USA). The data was analyzed using BD FACSDiva software version 6.1.1 
(Becton Dickinson), and the percentages of cells at each phase of the cell cycle were 
presented as donut charts by using GraphPad Prism 6 software (GraphPad Software, 
La Jolla, CA). 
 
Realtime PCR 
Total mRNA of INT407 cells treated with HhepCDT, HI-HhepCDT, HhepCdtA, 
HhepCdtB, HhepCdtC, CjejCDT, HI-CjejCDT, CjejWT WCL, CjejKO WCL, 
CjejComp WCL or blank medium in 24-well plates was extracted by using mRNA 
purification kit (Qiagen, Valencia, CA). After first strand cDNA synthesis by using a 
reverse transcription kit (ABI, Grand Island, NY), RT-PCR amplification of IL-6, IL-
8, IL-24 and 18S mRNA was carried out by using specific Taqman probes (ABI, 
Grand Island, NY) according to the manufacture’s instruction and determination of 
relative mRNA expression level of each cytokine. Data were normalized to 18S 
mRNA and expressed as fold increase over corresponding levels of mRNA from 
INT407 cells incubated in the presence of control medium on day 0. 
 
Cytokine protein expression assay 
Supernatants from INT407 cells treated with HhepCDT, HI-HhepCDT, CjejCDT, HI-
CjejCDT or blank medium were harvested on day 0, 3, 5, and 7, centrifuged at 10,000 
x g for 1 minute, and the supernatant was placed at -80°C until needed. The 
concentrations of IL-6 and IL-8 were determined by using a commercially-available 
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fluorescent bead multiplex cytokine assay as described by the manufacturer (R&D 
Systems, Minneapolis, MN) and analyzed by using a Bio-plex 200 machine (Bio-Rad, 
Hercules, CA). The relative concentration of cytokine was normalized on the basis of 
total number of viable INT407 cells per well.  
 
Data analysis 
Statistical analysis was done by using Student t-test with p<0.05 considered significant 
and displayed by using GraphPad Prism 6 software (GraphPad Software). For cell 
growth determinations, the number of viable cells at one time point was compared 




CDT causes cell growth arrest  
C. jejuni recombinant CDT is known to cause cell cycle arrest, its activity requires the 
formation of tripartite holotoxin composed of three subunits CdtA, CdtB and CdtC, 
and none of the subunits alone exhibits any toxicity to intestinal epithelial cells (35). 
To investigate the possibility of cellular senescence induced by CjejCDT, we used 
recombinant HhepCDT and CjejCDT holotoxin to stimulate human intestinal 
epithelial cell INT407 cells in a long time of period (up to 7 days) in a concentration 
that did not promote cell towards apoptosis or kill them, but still made cell show CDT 
intoxication effect such as cell distension. HhepCDT and CjejCDT intoxicated 
INT407 cells did not proliferate, and the number of cell did not decrease significantly 
either in the 7-day observation period (Figure 2.1A&B.). In order to prevent the over-
confluent growth in the 7-day long experiment, the starting number of non-intoxicated 
cells in Figure 2.1A was ten-fold fewer than that of the HhepCDT intoxicated cell 
cultures; the starting number of non-intoxicated cells for time point at day 7 in 
Figure1. B was ten-fold fewer than that of CjejCDT intoxicated. The medium control, 
HI-CjejCDT and HI-HhepCDT treated cells continued proliferating during the 7-day 
observation period. It suggests that CDT is able to cause cell growth arrest up to 7 
days, but heat inactivated CDT is not. Any of HhepCdtA, HhepCdtB and HhepCdtC 
alone does not cause cell growth arrest, suggesting the single CDT subunit does not 
cause the same cytotoxicity, and a CDT holotoxin is required to arrest cell growth as 
previously described.     
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In order to further rule out that cell growth arrest does not result from CdtA and CdtC 
subunits, or any contamination from the preparation of recombinant CDT protein, C. 
jejuni whole cell lysate (WCL) made from CjejWT, CjejKO and CjejComp was used 
to intoxicate INT407 cells. As shown in Figure1.B, CjejWT WCL and CjejComp 
WCL lead to cell growth arrest, whereas CjejKO WCL did not. It strongly supports 
that CDT causes cell growth arrest, and CdtB is the active subunit responsible for 
cytotoxicity.  
 
CDT is known to trigger DDR, which leads to cell cycle arrest in fibroblasts, epithelial 
and endothelial cell (22-24, 29). In less than 24 hours, C. jejuni CDT intoxicated HeLa 
cells show DDR such as the formation of Rad50 foci and γ-H2AX (24). Since 
recombinant HhepCDT, CjejCDT and C. jejuni WCL intoxicated INT407 cells exhibit 
significant growth arrest (Figure 2.1), DDR may be elevated consistently over time. 
We checked γ-H2AX formation over time in intoxicated INT407 cells. γ-H2AX in 
HhepCDT, CjejCDT,  CjejWT WCL and CjejComp WCL intoxicated INT407 cells 
was formed at day 3 post-intoxication and maintained consistently at a significantly 
greater level over the 7-day observation period (Figure 2.2A&B), however only basal 
levels of γ-H2AX formation were observed in the non-intoxicated groups of cells 
(medium control, HI-HhepCDT, HI-CjejCDT and CjejKO WCL) (Figure 2.2A&B). 
Immunofluorescence staining of γ-H2AX (Figure 2.2C) showed that CjejWT WCL 
and CjejComp WCL intoxicated cells had γ-H2AX staining in their enlarged nucleus, 
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but CjejKO WCL treated cells looked the same as the medium control, and had very 
few spots of γ-H2AX staining.  Cell cycle flow cytometry analysis confirmed that, at 
day 3, day 5 and day 7 post treatment, the percentage of G2/M phase cells in 
HhepCDT intoxicated cells are 67.5%, 54.6% and 45.5%; in CjejCDT intoxicated 
cells are 73.2%, 64.2% and 60.5%; in CjejWT WCL intoxicated cells are70.9.0%, 
69.9% and 62.7%; in CjejComp WCL intoxicated cells are 83.5%, 73.9% and 77.7%. 
HI-HhepCDT, HI-CjejCDT, and CjejKO WCL treated cells multiplied in the same 
pattern as medium control cells, and did not have cell cycle arrest (Figure 2.3). 
Overall, it clearly indicates that recombinant CDT or CjejWT WCL (which had active 
CdtB subunits) intoxicated cells stop proliferation, but are still viable throughout the 
7-day period of intoxication; CDT induces cell cycle arrest by triggering DDR in a 
manner dependent on CdtB activity.  
 
CDT induces senescence-associated β-galactosidase expression and senescence 
associated secretion phenotype 
CDT intoxicated INT407 cells exit cell cycle permanently, but are still alive. 
Presumably, this occurs as a result of cellular senescence.  In order to tell whether 
CDT intoxicated cells actually undergo cellular senescence or not, two more 
senescence markers were checked, As shown in Figure 2.4, at day 3, HhepCDT, 
CjejCDT, CjejWT WCL and CjejComp WCL intoxicated INT407 cells were 
distended, and some of the cells also showed large blue senescence-associated β-
galactosidase positive staining; at day 5 and day 7, most of the cells became 
 96 
senescence-associated β-galactosidase positive (Figure 2.4). However, medium 
control, HI-HepCDT, HI-CjejCDT and CjejKO WCL treated INT407 cells appeared 
normal in size and only few cells showed very small spots of blue senescence-
associated β-galactosidase staining (Figure 2.4).  
 
IL-6 and IL-8 are two cytokines up-regulated in senescence associated secretion 
phenotype, so realtime PCR was performed to evaluate the mRNA expression levels 
of IL-6 and IL-8. Compared with medium control INT40-7 cells, HhepCDT 
intoxicated INT407 cells had significantly increased IL-6 mRNA expression, from 
approximately 4-fold at day 3 to 20- fold at day 7, and IL-8 mRNA from 7-fold at day 
5 to 14- fold at day 7 (Figure 2.5A); CjejCDT intoxicated had a gradual significantly 
increased IL-6 mRNA expression from approximately 24 fold at day 3 to 90 fold at 
day 7, and IL-8 mRNA expression from 4 fold at day 3 to 10 fold at day 7 (Figure 
2.5B). In CjejWT WCL intoxicated INT407 cells, both of IL-6 and IL-8 mRNA 
expression increased approximately 2 fold for both at day 5 and 7. In CjejComp WCL 
intoxicated INT407 cells, IL-6 mRNA expression was up-regulated about 2, 2.5 and 6 
fold at day 3, 5 and 7 separately, and IL-8 mRNA expression was also raised from 
about 2.5 and 10 fold at day 5 and 7.  However, compared with medium control cells, 
HI-HhepCDT, HI-CjejCDT and CjejKO WCL treated cells did not have a significant 
up-regulation of IL-6 and IL-8 mRNA expression.  Corresponding to mRNA 
expression, IL-6 protein concentration in the supernatant of HhepCDT and CjejCDT 
intoxicated cells started to increase significantly from day 3 or day5, and IL-8 protein 
concentration begun to escalate significantly from day 5 or day 7 (Figure 2.5D&E).  
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Except for the increased expression of IL-6 and IL-8, we occasionally also observed a 
striking increase of IL-24 mRNA expression in HhepCDT (Figure 2.5A) (12.6 fold at 
day 5, 59 fold at day 7), CjejCDT (Figure 2.5B) (2.8 fold at day 3; 21 fold at day 5; 29 
fold at day 7), CjejWT WCL (Figure 2.5C) (2.9 fold at day 5; 7 fold at day 7) and 
CjejComp WCL (Figure 2.5C) (4 fold at day 5; 13.8 fold at day 7) intoxicated INT407 
cells at day 5 and . IL-24, belonging to Il-10 family of cytokines, is a tumor growth 
suppressor (36), but its role in cellular senescence has not been well described.  The 
significant increase of IL-24 mRNA expression in CDT intoxicated cells cellular 
senescence suggests it might get involved in CDT-induced cellular senescence. 
Generally, HhepCDT and CjejCDT intoxicated INT407 cells appear to show 
senescence-associated β-galactosidase expression and have senescence associated 
secretion phenotype – up-regulation of IL-6 and IL-8.  
 
In conclusion, we have shown that recombinant HhepCDT and CjejCDT proteins and 
C. jejuni WCL cause cell growth arrest and DNA damage, induce senescence-
associated β-galactosidase expression and stimulate SASP in human epithelial INT407 
cell. Based with evidence of these three striking cellular senescence markers, we can 
conclude in vitro C. jejuni CDT is the very potent toxin that induces cellular 
senescence in epithelial cells; CdtB is critical for the CDT induced cytotoxicity, but 





Figure 2.1 CDT intoxicated H407 cells do not preliterate. 
H407 cells were plated into 24 well-plates, and treated with recombinant protein 
(HhepCDT, HI-HhepCDT, HhepCdtA, HhepCdtB, HhepCdtC and CjejCDT), C. 
jejuni WCL (CjejWT, CjejKO and CjejComp) or blank medium (control). The number 
of viable cells was determined by trypan blue exclusion at indicated time points. In 
Control, 10 x less of the initial number of cells were used for a confluent cell growth 
at day 7. In each treatment, the number of viable cells from day 1 was compared with 
the previous time point inside the same treatment for statistical significance analysis. 
(A), 10 x less of the initial number of cells were used for all non HhepCDT intoxicated 
cells; (B), 10 x less of the initial number of cells were used for a confluent cell growth 
at day 7 in medium control and CjejKO WCL treatments. In each treatment, the 
number of viable cells at each time point (except day 0) was compared with the 
previous time point inside the same treatment for statistical significance analysis of 
cell growth. The number of viable cells increases from day 3 to day 7 in the medium 
control, and HI-HhepCDT, HhepCdtA, HhepCdtB, HhepCdtC and CjejKO WCL 
treatments. There was not significant cell growth in the cells intoxicated with 
HhepCDT, CjejCDT, CjejWT WCL and CjejComp WCL. Each treatment at every 
time point was done in triplicate. Data shown are from one of three independent 







Figure 2.2 Formation of γ-H2AX is up regulated in CDT intoxicated H407 cells.  
Lysates of H407 with different treatments whole cell lysates were prepared at 
indicated time points. (A&B), Immunoblotting was performed by using anti-γ-H2AX 
antibody or anti-β-actin antibody. (C), Immunofluorescence was conducted by using 
primary anti-γ-H2AX antibody and Alexa-fluo labeled secondary antibody, and DNA 
was stained with DAPI. Basel level of γ-H2AX formation is observed in the control 
medium, HI-HhepCDT, HhCdtA, HhCdtB, HhCdtC HI-CjejCDT and CjejKO WCL 
treated H407 cells, but a significant amount γ-H2AX is formed in the HhepCDT, 
CjejCDT, CjejWT WCL and CjejComp WCL intoxicated H407 cells from day 3 and 
throughout the 7-day observation period. Data shown are from one of three 
independent experiments. Immunofluorescence shows that the nucleus of H407 cells 
intoxicated with CjejWT WCL and CjejComp WCL are stained strongly with γ-H2AX 
and are enlarged, while nucleus of cells treated with control medium and CjejKO 































Figure 2.3 CDT intoxicated H407 cells are arrested in G2/M cell phase. 
H407 cells treated with recombinant protein (HhepCDT, HI-HhepCDT, HhepCdtA, 
HhepCdtB, HhepCdtC and CjejCDT) and C. jejuni WCL (CjejWT, CjejKO and 
CjejComp) were disassociated from 6-well plates by trypsinization and stained with 
PI.  Flow cytometric analysis was performed to estimate the proportion of cells in 
G0/G1 (green), S (blue) and G2/M (red) phases. Cell cycle was represented as percent 
total number of cells in the donut chart. At day 1, there is no cell cycle difference 
observed among the H407 cells with different treatments. At day 3, 5, and 7, in 
contrast to control medium, HI-HhepCDT, HI-CjCDT and CjKO WCL treated H407 
cells, significant amounts of cells are arrested in G2/M phase in HhepCDT, CjCDT, 
CjWT WCL and CjComp WCL intoxicated H407 cells.   Data shown are from one of 















Figure 2.4 CDT intoxicated H407 cells show senescence associated β-
galactosidase staining.   After different treatments at indicated time points, H407 
cells were processed for in situ cytochemical detection of β-galactosidase at pH 6.0. 
CjCDT, CjWT WCL and CjComp WCL intoxicated cells are enlarged, and a 
significant number of cells is stained blue (β-galactosidase positive) in contrast to 
control (Medium only), HI-CjCDT and CjKO WCL treated cells at day 3, 5 and 7. 






Figure 2.5 mRNA and protein expression levels of SASP were increased in CDT 
intoxicated H407 cells. 
(A&B) After treatment with CjCDT, HI-CjCDT, CjWT WCL, CjKO WCL, CjComp 
WCL or medium only (control) at indicated time points, H407 cells total mRNA was 
purified and reverse-transcribed. IL-6, IL-8 and IL-24 cDNA levels were quantified by 
TaqMan real-time PCR, and normalized to 18S ribosomal RNA cDNA levels. Data 
were represented as fold of increase compared with the cDNA level at day 0. (C) 
Supernatant of H407 cells co-incubated with CjCDT, HI-CjCDT or blank medium 
(Control) was harvested, and the number of viable cells was also counted by trypan 
blue exclusion. Protein concentration of IL-6 and IL-8 in the supernatant was 
determined by using Fluorokine MAP human high sensitivity cytokine kit, and 
normalized to the production of cytokines by 1 x 106 cells. Error bars represent 













Since the discovery of CDT in 1988, which causes progressive cell distension and 
death (37), it has caught attention to investigate how CDT causes those effects and its 
potential role in diseases. High dose of  recombinant of  H. hepaticus CDT is reported 
to kill epithelial cells by inducing apoptosis via mitochondrial apoptotic pathway, and 
increased level of γ-H2AX formation was observed in the cells indicating of DNA 
damage (23). However, low dose and consistent H. hepaticus lysates were reported to 
promote genome instability and trigger the cell survival signal (18, 24, 28). It appears 
that in vitro CDT cytotixity varies by the amount of toxin applied to the cells.  So far, 
almost all of the studies focus on the cell death and cell cycle arrest induced by CDT 
in vitro. In this study, we characterized the changes of intestinal epithelial cells in 7-
day long intoxication with sub-lethal doses of recombinant HhepCDT, CjejCDT or C. 
jejuni WCL, and observed that intoxicated cells eventually underwent premature 
cellular senescence. Our study illustrates that C. jejuni  CDT induces cellular 
senescence, which is usually seen in aging and stresses such as drug induced DNA 
damage and oncogene malfunction (1). In addition, H. hepaticus and C. jejuni CDT 
elevates proinflammatory cytokine expression significantly during the process of 
cellular senescence.  
 
CDT from different bacteria has been shown to have the capacity to induce cell death 
or growth arrest in many types of cells such as epithelial cells, keratinocytes, 
fibroblasts, and endothelial cell lines (18, 23, 24, 38-42), but most of the experiments 
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are mainly executed in a short period of time no more than 5 days. Here we went 
further to intoxicate epithelial cells with CDT or bacterial WCL for 7 days. CDT 
intoxicated cells did not die, but exhibited persistent DNA damage. The intoxicated 
cells were enlarged, arrested in G2/M phase, and remained metabolically alive during 
the 7 day period intoxication. Similar phenomenon has been observed in a 5-day long 
intoxication of different endothelial cell lines with Escherichia coli CDT-V, and it 
appears to induce cell distension and irreversible G2/M arrest in a dose-dependent 
manner (29). We extended this report and demonstrated that C. jejuni CDT has the 
potential to cause long-term cell growth arrest in epithelial cells for up to 7 days, and 
intoxicated cells have persistent DDR. Considering that constitutive DDR contributes 
to the establishment and maintenance of cellular senescence (7, 43), another two 
senescent markers were checked to detect senescent cells in H. hepaticus and C. jejuni 
CDT intoxicated epithelial cells. The presence of senescence-associated β-
galactosidase activity and SASP confirmed that in vitro the sub lethal dose of C. jejuni 
CDT intoxication induced cellular senescence in intestinal e pithelial cells, which is a 
very different phenomenon from apoptosis induced by H. hepaticus CDT in the in 
vitro experiments we have previously reported (23). It is well known that CdtA and 
CdtC are the subunits that are responsible to transport active CdtB subunit into the cell 
(42), and it is no surprise to see none of the three subunits of H. hepaticus CDT alone 
causes any cell damage, suggesting that the complete holotoxin of CDT is required for 
its cytotoxicity in vitro. C. jejuni CDT KO and Comp isogenic strains allowed us to 
exclude the possibility that contaminant from preparing recombinant CDT protein 
might be involved in inducing senescence, and validate  that CDT intoxication results 
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in cellular senescence. Surprisingly, a very low concentration of CjejWT and 
CjejComp WCL (400ng/ml and 80ng/ml respectively) is enough to induce cellular 
senescence. Given that without cell membrane enrichment, CDT in the bacteria is too 
limited to be detected by immunoblotting (15), presumably,  the actually amount of 
CDT in CjejWT and CjejComp WCL might be far less than 1 ng/ml. In contrast, much 
higher concentration of recombinant CDT protein (20ug/ml) is needed to induce 
cellular senescence. This discrepancy is probably due to the low efficacy in 
recombinant protein refolding and CDT complex resembling, when the recombinant 
CDT holotoxin was prepared. 
 
Epithelial cells treated with high concentration of HhepCDT undergo apoptosis (23). 
Under intermediate concentration CDT, our data show, DNA damage is not repairable, 
but not enough to trigger the apoptosis either, and epithelial cells commit to 
senescence. Presumably less deleterious amount of CDT intoxication induces cell 
cycle arrest temporarily which allows the repair mechanisms to repair the damage.  
Persistent genotoxic stress during chronic infection by CDT-producing bacteria might 
contribute to neoplastic transformation by induction of genomic instability (28, 42). H. 
hepaticus has been correlated with the development of hepatocellular carcinoma in 
A/JCr mice and colorectal cancer in immunodeficient mice (44). In this scenario, 
cellular senescence would be beneficial in the defense to prevent or delay neoplastic 
transformation initiated by CDT-induced DNA damage. However cellular senescence 
could also be detrimental, as cellular senescence is connected with the disruption of 
tight junctions and increase of monolayer permeability in vitro (45). That C. jejuni 
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infection alters the tight junction formed by epithelial monolayer cells, and increases 
its permeability in vitro (46-48), implies CDT-induced cellular senescence could be a 
mechanism used by bacteria to break the integrity of tight junction and facilitate its 
invasion.  
 
C. jejuni CDT induced senescent INT407 cells have a significant increased expression 
of IL-6, IL-8 and IL-24, of which IL-6 and IL-8 are among the cytokines found in 
SASP. Interestingly, persistent infection accompanied with chronic inflammation is a 
common feature of many CDT-producing bacteria (42), suggesting that induction of 
SASP might be more prevalent than previously recognized. Consistent with this 
suggestion is the demonstration of pro-inflammatory cytokine responses of various 
CDT intoxicated cells in short term in vitro experiments, including INT407 cells (49, 
50), HeLa (51) and T84 (25, 51-53). Even though there are also CDT-independent 
mechanisms of IL-8 stimulation in C. jejuni infection, which depends on C. jejuni 
invasion (15),  our data shows that CDT intoxication might still greatly contribute to 
the IL-8 production.  In the immune response, continuous IL-8 expression results in 
consistent neutrophil infiltration, which is a definite observation in C. jejuni infected 
IL-10-/- mice (54).  IL-6 is a proinflammatory cytokine, and critical in directing innate 
to adaptive immune response (55). After 10 month of infection with H. hepeticus or its 
isogenic CDT mutant strain, activation of NF-κB, and up-regulation of IL-6 mRNA 
and other proinflammatory cytokines were detected in H. hepeticus infected mouse 
liver, but not in CDT mutant strain infected mouse liver (56). NF-κB is reported to be 
the major inducer of SASP (57), and the IL-6 and IL-8 increase in the HhepCDT 
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induced senescence is likely through NF- κB pathway. LPS of C. jejuni and live C. 
jejuni infection stimulate IL-6 expression in intestinal epithelial cells. However, little 
is known about IL-6 function during C. jejuni infection in vivo.  Proinflammatory 
cytokines IL-6 and IL-8 are commonly considered as enhancers of tumorigenesis (58) , 
and on the other hand cellular senescence is taken as anti-tumorigenesis mechanisms. 
IL-6 and IL8 may facilitate maintaining the phenotype of senescent cells, but they may 
also favor the tumorigenesis in the cells nearby non-autonomously. Further 
investigation is needed to illustrate the role of IL-6 and IL-8 in HhedpCDT and 
CjejCDT induced cellular senescence.  
 
Significant increase of IL-24 was observed in CDT induced senescent cells, and its 
relationship with cellular senescence has not been described.  IL-24 classified as IL-10 
gene family has the property of inducing cancer cell apoptosis, and its expression is 
associated with immune system such as thymus, spleen and peripheral blood 
leukocytes (59). The expression of IL-24 can be detected from human colonic 
subepethelial myofibroblasts in the inflamed mucosa of IBD patients, and IL-24 
suppresses inflammatory responses in the intestine mucosa (60). The greater level of 
IL-24 mRNA expression in CDT induced senescent epithelial cells implicates IL-24 
may be essential in maintaining the intestinal homeostasis by eliminating cancer cells, 
and balancing the inflammatory response resulting from IL-6 and IL-8. The role IL-24 
in cellular senescence is very unclear.  
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In conclusion, we demonstrated that bacteria CDT can damage DNA in INT407 
epithelial cells, cause cell cycle arrest, and induce cellular senescence. Persistent CDT 
intoxication leads to significant increased expression of proinflammatory cytokines.  It 
suggests CDT is  a potent inducer of cellular senescence in vitro, which might not only 
be a defensive mechanism fighting against tumorigenesis during infection caused by H. 
hepaticus or C. jejuni, but also contributes to bacteria invasion and pathogenesis.  
Taken together, our findings elucidate a basic mechanism of disease and suggest 
potential pathway to neoplastic transformation associated with CDT-producing 
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Supplemental material and methods 
 
Construction of C. jejuni CDT isogenic mutants  
The cdtB genes of C. jejuni strains ET46-36-20, isolated from macaques with 
campylobacteriosis (29) were disrupted to produce ΔcdtB mutants, and strain ET46-
36-20 was complemented with a full-length cdtABC operon. The constructs have been 
sequenced and immunoblotted (Figure 2.6). Briefly, for directional cloning, the full 
length cdtABC operon of C. jejuni was amplified by PCR with cdtAF and cdtCR 
oligonucleotides (Figure 2.6A), to make pBSIIKS+-cdtABC (Strategen, La Jolla, CA). 
The cdtB gene was disrupted by insertional mutagenesis of a kanamycin resistance 
cassette which can function in both C. jejuni and E. coli, (shuttle vector pRY107, 
kindly provided by Dr. P. Guerry, Enteric Diseases Department, Naval Medical 
Research Center, MD; 139), into a unique EcoRI site of cdtB at position 419 and 
selection with 50 μg/ml of kanamycin. The ET46-36-20 strain with a disrupted cdtB 
gene was complemented with a 2.9-kb fragment encompassing the cdtABC operon 
amplified by PCR, ligated into pRY111, and selection with 20µg/ml of 
chloramphenicol. Sequencing of the recombinant shuttle vector cdtABC-01 revealed 
the cdtABC transcribed in the same orientation as the lacZ promoter, and cdtABC-02, 
with the cdtABC in the opposite orientation. Complementation of the ET46-36-20 
strain with a disrupted cdtB gene was accomplished by conjugation with E. coli 
harboring empty pRY111, cdtABC-01, or cdtABC-02 and selection with 200 µg/ml of 
kanamycin and 15 µg/ml of chloramphenicol. Enriched membrane preparations of 
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each strain were examined by immunoblot with hyperimmune rabbit polyclonal 
antibodies prepared against C. jejuni His6-CdtB fusion protein. As expected, the C. 
jejuni ET46-36-20 WT and isogenic strains with inactivated cdtB gene complemented 
with the full length cdtABC operon (ΔcdtBComp), and recombinant C. jejuni CdtB 
fusion protein displayed a band of approximately 29-kDa molecular mass (Figure 
2.6B). Conversely, the C. jejuni ET46-36-20 ΔcdtB mutant and C. jejuni ET46-36-20 
transformed with the empty vector pRY111 showed no band, confirming that these 










Figure 2.6. Construction and expression of recombinant C. jejuni CdtA, CdtB 
and CdtC.  
A. C. jejuni cdtABC operon with location of oligonucleotide primers for 
overexpression of CdtB fusion protein (cdtBCjF and cdtBCjR), directional 
inactivation of cdtB by insertion of a kanamycin (KanR) antibiotic resistance cassette 
(CDTAF2 and CDTCR1; cdtAF and cdtCR), and complementation with full length 
cdtABC operon (CDT-F1 and CDT-R1). B. Immunoblot analysis of CdtB obtained 
from enriched membrane fractions of C. jejuni ET46-36-20. Lanes: (1) wild-type 
(WT), (2) cdtB isogenic mutant strain complemented with full length cdtABC operon 
in a 3’ to 5’ orientation (ΔcdtB + pcdtCBA-01); (3) ΔcdtB; (4) ΔcdtB complemented 
with full length cdtABC operon in a 5’ to 3’ orientation (ΔcdtB + pcdtABC-02); (5) 
ΔcdtB complemented with empty vector (ΔcdtB + pRY111); and purified recombinant 
His6-tagged C. jejuni CdtB fusion protein as a positive control. The membrane was 
incubated with rabbit anti-C. jejuni His6-CdtB fusion protein followed by horseradish 
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Summary of findings 
 
CDT is a novel AB type genotoxins that has been found in a growing list of clinically-
important Gram negative bacterial pathogens (1). There are substantial in vitro 
evidences to support CDT contribution to DNA damage resulting in cell cycle arrest 
and apoptosis (1). In vivo, CDT has been linked to persistent bacterial colonization and 
pathogenesis of H. hepaticus and C. jejuni infection (2-4), and modulation of host 
immune response in H. hepaticus infection (5). Our studies focused on understanding 
the contribution of CDT produced by C. jejuni and H. hepaticus in induction of host 
innate immune response by intestinal epithelial cells and interaction with NETs.  
 
Because large numbers of PMNs are recruited at the site of intestinal infection during 
acute C. jejuni infection, Chapter 2 examined the contribution of CDT nuclease in 
NETs. This was justified on the basis of demonstrating NET formation within the 
intestinal lumen of rhesus macaque with spontaneous campylobacteriosis and co-
localization of C. jejuni within NETs. To investigate the interaction of C. jejuni with 
NETs we used PMNs derived from bone marrow of mice and peripheral blood of 
human beings. Although C. jejuni did not induce mouse or human NET formation in 
vitro, efficient trapping within NETs that was rescued by adding exogenous 
mammalian DNaseI was found. The lack of NET induction was not serotype-specific 
since three different strains of C. jejuni showed similar phenotypes, suggesting C. 
jejuni is not a potent NET inducer. The lack of significant differences in NETs 
induction, capture and killing between C. jejuni wild-type (CjejWT) compared to 
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isogenic ∆CDT (CjejKO) and ∆CDT complemented with CDT (CjejComp) mutant 
strains indicates that CDT might not contribute to bacterial escape from NETs. 
Nevertheless, NETs likely represent an important mechanism to control C. jejuni 
infection during acute infection of the gut (Figure 3.1).    
 
Because H. hepaticus and C. jejuni can persist in the intestine and interact with host 
intestinal epithelium, Capter 3 examined the kinetic of CDT interaction with human 
intestinal epithelial cells over 7 days. For these studies we used reconstituted 
recombinant C. jejuni and H. hepaticus CDT (CjejCDT and HhepCDT) and whole-cell 
lysates (WCL) of CjejWT and CjejKO and CjejComp isogenic strains. Our data 
showed that recombinant CDT, WCL from CjejWT and CjejComp induced premature 
cellular senescence characterized by arrest of cell proliferation that correlated with 
persistent DDR together with senescence-associated β-galactosidase expression and 
senescence-associate secretory phenotype (SASP). While greater concentration of 
recombinant CDT (20 ug/ml) was required for induction of cellular senescence, 
several fold less WCL (8 ng/ml) induced similar level of senescence-associated 
phenotype. Taken together our data demonstrate that in addition to cell cycle arrest 
and apoptosis, CDT can induce premature senescence of intestinal epithelial cells 
which might contribute to the pathogenesis of disease. 
 
Interaction of Campylobacter jejuni with NETs 
The lack of suitable laboratory animal models that mimic acute human intestinal 
infection (6) has greatly limited our understanding of the contribution of PMNs in 
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control of C. jejuni infection. Nevertheless, it is well-established that C. jejuni can 
elicit a robust IL-8 response in vitro (7-9) which is thought to play key role in host 
innate immune recruitment of PMNs at the site of intestinal infection. There are only 
few reports describing phagocytic killing of C. jejuni by PMNs (10); however, the 
recent discovery of NETs urged us to investigate the potential contribution of NETs to 
control of acute C. jejuni infection. Our demonstration of C. jejuni association with 
NETs in the intestinal tract of non-human primates with spontaneous acute 
campylobacteriosis suggested that NETs might be an important mechanism of host 
innate defense against C. jejuni infection. Moreover, on the basis of previous reports 
on the role of bacterial nucleases mediating escape of bacterial pathogens from NETs, 
we investigated the contribution of CjejCDT nuclease in interaction of C. jejuni with 
NETs. The in vitro findings that although C. jejuni did not induce mouse or human 
NET formation, but were efficiently captured and survived NET killing was 
unexpected. However, considering that PMNs interact with C. jejuni in the lumen of 
the intestine, an environment rich in bacteria and their products which are potent NET 
inducers (11) suggested that trapping of C. jejuni within pre-formed NETs might assist 
control of infection by eliminating bacteria through peristalsis, and thus, reduce 
bacteria load. Given that the stereotypical host response to C. jejuni infection is 
diarrhea, the release of large numbers of live bacteria in feces might promote 
transmission of the disease between susceptible hosts. We speculate that the close 














Figure 3.1 NETs in innate immune defense against Campylobacter jejuni 
intestinal infection.  C. jejuni colonization of the intestine elicits recruitment of host 
PMNs to the site of infection through bacterial induced intestinal epithelial cell 
expression of IL-8 chemokine. Non-specific NET induction by intestinal flora bacteria 
and their products can entrap C. jejuni preventing further colonization and epithelial 
cell invasion. Eventually, intestinal peristalsis and secretory diarrhea expedite the 
elimination of C. jejuni entrapped within NETs and further dissemination of the 
pathogens in the environment, and thus, transmission of disease. 
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advantage of providing an efficient mechanism of horizontal gene transfer including 
antibiotic resistance.  
 
The unexpected findings that CDT nuclease did not inhibit NET formation or mediate 
bacterial escape from NETs suggested that it is unlikely to contribute to bacterial 
resistance against this host innate defense mechansim. Because C. jejuni CDT is 
membrane-associated and has a weak DNase activity when compared with other 
bacterial nucleases that have been shown to mediate NET escape, the lack of 
contribution of CDT to NET interaction suggested a different pathogenetic role for 
this toxin. However, because of the limited viability of C. jejuni in vitro (maximum 4 
hour observation period in our studies), the interaction of C. jejuni with NETs in vivo 
was not fully assessed. Therefore possibility that C. jejuni are killed over a longer 
period of time cannot be excluded completely.  Moreover, additional factors within the 
intestinal lumen that might affect the biology of C. jejuni cannot be duplicated in our 
in vitro experiments including the role of bile acids increasing CDT expression and 
release (12).   
 
Induction of premature cellular senescence by CDT 
Cellular senescence is a well-established process associated with aging and various 
cellular stresses including chemical- and radiation-induced DNA damage and 
mitogenic oncogene (13-16); however, less is known about induction of premature 
cellular senescence in infectious diseases. Recently, the CDT of Haemophilus ducreyi 
(HducCDT) was shown to induce premature cellular senescence of fibroblast (17) and 
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promoted genome instability over long-term intoxication (18). Because H. hepaticus 
and C. jejuni are intestinal pathogens, we used human intestinal epithelial INT407 cell 
line to investigate the outcome of intoxication with sub-lethal concentrations of 
recombinant CDT and CDT holotoxin from whole cell lysate (WCL) within the 
context of a relevant in vivo infection microenvironment for these pathogens. 
Recombinant CjejCDT and HhepCDT proteins induced premature cellular senescence. 
The essential role of CdtB in induction of cellular senescence was further confirmed 
with C. jejuni CDT isogenic mutants and individual recombinant CDT subunits. The 
observation of CDT mediated cellular senescence and its senescence associate 
secretory phenotype (SASP) provides an exciting new perspective to our interpretation 
of the mechanism of C. jejuni pathogenesis within the context of host intestinal 
inflammatory bowel disease. 
 
Although persistent C. jejuni infection has only been documented in AIDS patients 
(19), chronic infection of immunocompetent marmosets with C. jejuni is characterized 
by large number of bacteria within the lumen of the colon extending into crypt lumena 
(Figure 3.2 A and B). on the basis of these observations we hypothesized that long-
term CDT-induced intoxication of intestinal epithelial cells might play a critical role in 
intestinal homeostasis and chronic inflammation.  
 
Within the intestine, stem cells located at the base of colonic crypts give rise to 






















Figure 3.2 Captive cotton top tamarins (CCT) with C. jejuni-associated colitis. 
Immunohistochemical staining of formalin-fixed and paraffin-embedded sections of 
colons obtained from CTT with naturally-acquired colitis with a C. jejuni-specific 
mouse monoclonal IgG2b antibody (MED-CLA201; Accurate Chem. & Scientific 
Corp., Westbury, NY). Note the large numbers of bacteria (red) in the lumen and 
inside crypt lumena. Avidin-biotin-alkaline phosphatase complex method and 
hematoxylin counterstain (20X original magnification). 
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our observations, we hypothesize that persistent colonization of intestinal crypts by 
large numbers of C. jejuni and the release of CDT induces premature senescence and  
induction of a SASP that contributes to chronic host inflammatory response. Because 
senescence is known to alter tight junctions and increase epithelial barrier permeability 
(21), this in turn might provide a suitable crypt microenvironment that promotes 
bacterial persistence within intestinal crypt lumena. Concurrently, the CDT-induced 
SASP might also contribute to alterations of the crypt microenvironment, but also to 
the chronic intestinal inflammatory response (22). Whether chronic intestinal 
inflammation promotes survival of C. jejuni within crypt lumena and dissemination 

















Figure 3.3 CDT interaction with colonic intestinal epithelial cells. The current 
proposed model of intestinal epithelial cell structure and kinetics consists of Lgr5+ve 
crypt base columnar (CBC) stem cells giving rise to transit amplifying (TA) 
progenitor cells which generate differentiated absorptive epithelial cells. Absorptive 
epithelial cells and TA cells are being replaced regularly; however, the stem cells are 
limited and have an extended life span. We propose that persistent colonization of 
intestinal crypts by C. jejuni can lead to CjejCDT-induced premature cellular 
senescence in stem cells leading to SASP and chronic inflammation. Both of these 
mechanisms adversely increase the intestinal epithelial barrier permeability favoring 





The combined medical burden of campylobacteriosis, inflammatory bowel disease and 
colon cancer to human health is beyond that of any other diseases of mankind. The 
pathogenesis of C. jejuni and H. hepaticus infection in general and the contribution of 
CDT to disease in particular are incompletely understood and represent a major 
hindrance to development of disease control strategies. Because of the lack of suitable 
laboratory animal model to study C. jejuni infection and disease, most of the current 
data including our own is based on in vitro model systems. Because CDT induces 
persistent premature senescence of cultured intestinal epithelial cells in vitro, future 
studies will correlate sequential intestinal epithelial cell kinetics with expression of 
DDR in animal models experimentally infected with CDT-producing bacterial 
pathogens. 
 
Because C. jejuni causes persistent intestinal colonization without significant intestinal 
inflammation in conventional laboratory mice, it is unlikely that premature cellular 
senescence is involved in this model. By contrast, experimental infection of 
immunodeficient mice with C. jejuni might provide an in vivo model to further 
delineate the role of NET in host innate defense.  Alternatively, a fetal rabbit intestine 
xenograft model can be extended to examine factors involved in short term host 
response to acute C. jejuni infection, particularly the role of NET.  By adding different 
bacterial components, the contribution of the intestinal flora could be further 
investigated. Infection of xenografts with C. jejuni CDT isogenic mutant strains could 
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provide direct evidences about the role of CDT in C. jejuni interaction with NETs. 
 138 
 
                                                                  REFERENCES 
 
1. Jinadasa, R. N., S. E. Bloom, R. S. Weiss, and G. E. Duhamel. 2011. 
Cytolethal distending toxin: a conserved bacterial genotoxin that blocks cell 
cycle progression, leading to apoptosis of a broad range of mammalian cell 
lineages. Microbiology 157: 1851-1875. 
2. Young, V. B., K. A. Knox, and D. B. Schauer. 2000. Cytolethal distending 
toxin sequence and activity in the enterohepatic pathogen Helicobacter 
hepaticus. Infection and immunity 68: 184-191. 
3. Fox, J. G., A. B. Rogers, M. T. Whary, Z. Ge, N. S. Taylor, S. Xu, B. H. 
Horwitz, and S. E. Erdman. 2004. Gastroenteritis in NF-kappaB-deficient mice 
is produced with wild-type Camplyobacter jejuni but not with C. jejuni lacking 
cytolethal distending toxin despite persistent colonization with both strains. 
Infection and immunity 72: 1116-1125. 
4. Young, V. B., K. A. Knox, J. S. Pratt, J. S. Cortez, L. S. Mansfield, A. B. 
Rogers, J. G. Fox, and D. B. Schauer. 2004. In vitro and in vivo 
characterization of Helicobacter hepaticus cytolethal distending toxin mutants. 
Infection and immunity 72: 2521-2527. 
5. Pratt, J. S., K. L. Sachen, H. D. Wood, K. A. Eaton, and V. B. Young. 2006. 
Modulation of host immune responses by the cytolethal distending toxin of 
Helicobacter hepaticus. Infection and immunity 74: 4496-4504. 
6. Young, K. T., L. M. Davis, and V. J. Dirita. 2007. Campylobacter jejuni: 
molecular biology and pathogenesis. Nature reviews. Microbiology 5: 665-679. 
 139 
 
7. Hickey, T. E., S. Baqar, A. L. Bourgeois, C. P. Ewing, and P. Guerry. 1999. 
Campylobacter jejuni-stimulated secretion of interleukin-8 by INT407 cells. 
Infection and immunity 67: 88-93. 
8. MacCallum, A., G. Haddock, and P. H. Everest. 2005. Campylobacter jejuni 
activates mitogen-activated protein kinases in Caco-2 cell monolayers and in 
vitro infected primary human colonic tissue. Microbiology 151: 2765-2772. 
9. Watson, R. O., and J. E. Galan. 2005. Signal transduction in Campylobacter 
jejuni-induced cytokine production. Cellular microbiology 7: 655-665. 
10. Walan, A. S. A., C. Dahlgren, E. KihlstrÖM, O. Stendahl, and R. Lock. 1992. 
Phagocyte killing of Campylobacter jejuni in relation to oxidative activation. 
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 
100: 424-430. 
11. Papayannopoulos, V., and A. Zychlinsky. 2009. NETs: a new strategy for 
using old weapons. Trends in immunology 30: 513-521. 
12. Hickey, T. E., A. L. McVeigh, D. A. Scott, R. E. Michielutti, A. Bixby, S. A. 
Carroll, A. L. Bourgeois, and P. Guerry. 2000. Campylobacter jejuni cytolethal 
distending toxin mediates release of interleukin-8 from intestinal epithelial 
cells. Infection and immunity 68: 6535-6541. 
13. Kirkwood, T. B. L., and S. N. Austad. 2000. Why do we age? Nature 408: 
233-238. 
14. Parrinello, S., E. Samper, A. Krtolica, J. Goldstein, S. Melov, and J. Campisi. 
2003. Oxygen sensitivity severely limits the replicative lifespan of murine 
fibroblasts. Nature cell biology 5: 741-747. 
 140 
 
15. di Fagagna, F. D. 2008. Living on a break: cellular senescence as a DNA-
damage response. Nature Reviews Cancer 8: 512-522. 
16. Minamino, T., H. Miyauchi, T. Yoshida, Y. Ishida, H. Yoshida, and I. 
Komuro. 2002. Endothelial cell senescence in human atherosclerosis - Role of 
telomere in endothelial dysfunction. Circulation 105: 1541-1544. 
17. Blazkova, H., K. Krejcikova, P. Moudry, T. Frisan, Z. Hodny, and J. Bartek. 
2010. Bacterial intoxication evokes cellular senescence with persistent DNA 
damage and cytokine signalling. Journal of cellular and molecular medicine 
14: 357-367. 
18. Guidi, R., L. Guerra, L. Levi, B. Stenerlow, J. G. Fox, C. Josenhans, M. G. 
Masucci, and T. Frisan. 2013. Chronic exposure to the cytolethal distending 
toxins of Gram-negative bacteria promotes genomic instability and altered 
DNA damage response. Cellular microbiology 15: 98-113. 
19. Coker, A. O., R. D. Isokpehi, B. N. Thomas, K. O. Amisu, and C. L. Obi. 
2002. Human campylobacteriosis in developing countries. Emerging infectious 
diseases 8: 237-244. 
20. Barker, N., and H. Clevers. 2010. Leucine-rich repeat-containing G-protein-
coupled receptors as markers of adult stem cells. Gastroenterology 138: 1681-
1696. 
21. Krouwer, V. J., L. H. Hekking, M. Langelaar-Makkinje, E. Regan-Klapisz, and 
J. A. Post. 2012. Endothelial cell senescence is associated with disrupted cell-
cell junctions and increased monolayer permeability. Vascular cell 4: 12. 
 141 
 
22. Edelblum, K. L., and J. R. Turner. 2009. The tight junction in inflammatory 
disease: communication breakdown. Current opinion in pharmacology 9: 715-
720. 
 
 
 
 
 
 
 
 
 
 
 
 
